[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_03c0bb81-8899-434d-8036-3293f53f24f4":3,"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":105,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:03c0bb81-8899-434d-8036-3293f53f24f4,\"}":953},{"code":4,"data":5,"meta":20},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":22,"manageAffiliations":41,"indexDatabases":56,"url":94,"thumbnailPath":20,"statistic":95,"gsStatistic":20,"type":104,"analyzePriority":20},"03c0bb81-8899-434d-8036-3293f53f24f4","2024-04-11T03:50:44.143+00:00","2025-11-21T09:48:20.844+00:00",[],"Investigational-New-Drugs",{"issn":12,"title":14,"eissn":16},{"VOID":13},"1573-0646",{"EN":15},"Investigational New Drugs",{"VOID":17},"0167-6997","PUBLISHER","PENDING",null,0,[23,29,35],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":25,"label":26,"description":28,"parentId":20,"standard":20,"scholarHubFieldId":20},"8d3ee16d-8f93-4e34-b94e-cd3a00dde338",[],{"EN":27},"Pharmacology (medical)",{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":31,"label":32,"description":34,"parentId":20,"standard":20,"scholarHubFieldId":20},"d9687dc3-fd83-46ff-aef4-1925044c24eb",[],{"EN":33},"Oncology",{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":37,"label":38,"description":40,"parentId":20,"standard":20,"scholarHubFieldId":20},"8b51d244-613f-4ff9-b308-d32de7c33ed9",[],{"EN":39},"Pharmacology",{},[42,49],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":44,"slug":20,"properties":45,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":48,"statistic":20},"26a19206-5cad-4456-bb2f-49abd254fbc6",[],{"title":46},{"EN":47},"SPRINGER",[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":51,"slug":20,"properties":52,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":55,"statistic":20},"057c9157-8e5c-4434-9423-dd9cf883d40d",[],{"title":53},{"EN":54},"Kluwer Academic Publishers",[],[57,75],{"id":58,"indexDatabase":59,"url":71,"indexYears":20,"academicFieldIds":72,"indexDatabaseRanking":20},"b8251850-8728-4b50-8761-021cd6387d9d",{"id":60,"createTime":20,"updateTime":20,"relativeEntities":61,"label":62,"description":64,"key":67,"publicationTags":68,"standard":20},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":63,"VI":63},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":65,"VI":66},"SCIE database","Cơ sở dữ liệu SCIE","scie",[69,70],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0167-6997",[73,74],"2b943d65-24a8-4546-9232-a1e32c12cb6c","248e54de-c562-4c06-8a10-d7f8a37c06fe",{"id":76,"indexDatabase":77,"url":87,"indexYears":88,"academicFieldIds":89,"indexDatabaseRanking":93},"455795cb-5eef-478a-9260-b8e238d51947",{"id":78,"createTime":20,"updateTime":20,"relativeEntities":79,"label":80,"description":82,"key":84,"publicationTags":85,"standard":20},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":81,"VI":81},"Scopus - Elsevier",{"EN":81,"VI":83},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[86],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F22477","1983-2025",[90,91,92],"46eddd1f-e049-4237-8609-9d60083086ad","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","e39d1b91-b03d-48ed-87bb-ab5b714ad558","SCOPUS__Q1","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F10637",{"impactFactor":21,"impactFactorByYear":96,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":98,"totalCitation":21,"totalCitationByYear":102,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":103,"hindexLast5Year":21,"hindex":21},{},31,{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},1,2,3,{},{},"JOURNAL",{"meta":106,"data":108},{"total":107},"117",[109,152,340,389,473,568,629,740,804,838],{"id":110,"createTime":111,"updateTime":112,"relativeEntities":113,"slug":114,"properties":115,"entityType":18,"verifyStatus":127,"verifyTime":128,"verifyNote":20,"languages":129,"translateLanguages":20,"viewCount":21,"subjectFields":132,"manageAffiliations":133,"indexDatabases":134,"url":135,"thumbnailPath":20,"statistic":20,"gsStatistic":136,"type":104,"analyzePriority":20},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-08-27T01:57:29.562+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":116,"issn":118,"title":120,"introduce":123,"gsId":125},{"VOID":117},"VN",{"VOID":119},"08667535",{"EN":121,"VI":122},"Journal of Tropical Science and Engineering","Tạp chí Khoa học và Công nghệ nhiệt đới",{"EN":124},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":126},"MS2_GJQAAAAJ","VERIFIED","2025-10-27T06:27:25.058+00:00",[130,131],"VI","EN",[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":20,"impactFactorByYear":20,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":137,"totalPublicationByYear":138,"totalCitation":140,"totalCitationByYear":141,"totalCitationPerPublication":149,"totalCitationPerPublicationByYear":150,"hindexLast5Year":101,"hindex":101},483,{"0":99,"2020":99,"2021":99,"2022":99,"2024":99,"2025":139,"2026":101},475,117,{"2017":99,"2018":99,"2019":142,"2020":143,"2021":143,"2022":144,"2023":145,"2024":146,"2025":147,"2026":148},4,5,11,6,7,53,15,0.24,{"2020":143,"2021":143,"2022":144,"2024":146,"2025":151,"2026":143},0.11,{"id":153,"createTime":154,"updateTime":112,"relativeEntities":155,"slug":156,"properties":157,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":165,"subjectFields":166,"manageAffiliations":167,"indexDatabases":180,"url":197,"thumbnailPath":20,"statistic":198,"gsStatistic":289,"type":104,"analyzePriority":20},"cc3aedc1-bd17-441e-b403-4be82349b362","2023-05-29T12:05:16.902+00:00",[],"Vietnam-Journal-of-Mechanics",{"country":158,"issn":159,"title":161,"gsId":163},{"VOID":117},{"VOID":160},"08667136",{"EN":162},"Vietnam Journal of Mechanics",{"VOID":164},"B98qpzgAAAAJ",29,[],[168],{"id":169,"createTime":20,"updateTime":20,"relativeEntities":170,"slug":20,"properties":171,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":178,"parentIds":179,"statistic":20},"5bf72910-eb8d-41eb-b358-ea294f24f765",[],{"title":172,"country":175,"abbreviation":176},{"EN":173,"VI":174},"Vietnam Academy of Science and Technology","Viện Hàn lâm Khoa học và Công nghệ Việt Nam",{"VOID":117},{"VOID":177},"VAST","https:\u002F\u002Fvast.gov.vn\u002F",[],[181],{"id":182,"indexDatabase":183,"url":193,"indexYears":194,"academicFieldIds":195,"indexDatabaseRanking":20},"61d05d3d-1119-4247-9062-3944e6a8afd5",{"id":184,"createTime":20,"updateTime":20,"relativeEntities":185,"label":186,"description":188,"key":190,"publicationTags":191,"standard":20},"7c6668cf-5dbb-472f-ac65-0e3d0d95e1c2",[],{"EN":187,"VI":187},"ACI - Asean Citation Index",{"EN":189,"VI":189},"Cơ sở dữ liệu ACI","aci",[192],"ACI","https:\u002F\u002Fasean-cites.org\u002Fjournal_info?jid=10758","2018-2022",[196],"007635a4-2624-49b8-a8f3-fec188e6a80e","http:\u002F\u002Fvjs.ac.vn\u002Findex.php\u002Fvjmech\u002Findex",{"impactFactor":21,"impactFactorByYear":199,"i10Index":218,"i10IndexLast5Year":100,"totalPublication":219,"totalPublicationByYear":220,"totalCitation":238,"totalCitationByYear":239,"totalCitationPerPublication":257,"totalCitationPerPublicationByYear":258,"hindexLast5Year":241,"hindex":241},{"1994":200,"1995":201,"1997":151,"1998":202,"1999":201,"2000":203,"2001":204,"2002":203,"2003":203,"2004":205,"2005":206,"2006":207,"2007":201,"2008":206,"2010":208,"2011":209,"2012":210,"2013":211,"2014":201,"2015":212,"2016":207,"2017":212,"2018":213,"2019":205,"2020":214,"2021":215,"2022":211,"2023":216,"2024":217},0.12,0.08,0.05,0.02,0.1,0.15,0.14,0.09,0.07,0.21,0.73,0.52,0.13,0.26,0.36,0.61,0.64,0.27,23,1046,{"1979":221,"1980":222,"1981":223,"1982":224,"1983":148,"1984":224,"1985":225,"1986":223,"1987":148,"1988":148,"1989":218,"1990":223,"1991":224,"1992":223,"1993":226,"1994":227,"1995":228,"1996":228,"1997":227,"1998":226,"1999":223,"2000":218,"2001":229,"2002":225,"2003":230,"2004":218,"2005":231,"2006":228,"2007":232,"2008":233,"2009":226,"2010":229,"2011":144,"2012":234,"2013":226,"2014":229,"2015":226,"2016":230,"2017":235,"2018":227,"2019":226,"2020":236,"2021":218,"2022":237,"2023":225,"2024":100},12,17,18,19,20,25,28,27,22,21,24,38,35,37,26,39,36,1403,{"1980":99,"1982":99,"1983":99,"1991":227,"1992":142,"1993":145,"1994":146,"1995":240,"1996":241,"1997":229,"1998":235,"1999":144,"2000":231,"2001":222,"2002":223,"2003":97,"2004":242,"2005":226,"2006":243,"2007":244,"2008":245,"2009":246,"2010":247,"2011":248,"2012":249,"2013":250,"2014":246,"2015":251,"2016":252,"2017":233,"2018":253,"2019":254,"2020":253,"2021":255,"2022":256,"2023":142},9,13,30,46,40,65,43,119,105,89,72,63,66,70,59,68,58,1.34,{"1980":259,"1982":202,"1983":208,"1991":260,"1992":261,"1993":149,"1994":262,"1995":263,"1996":264,"1997":265,"1998":266,"1999":215,"2000":266,"2001":267,"2002":268,"2003":269,"2004":270,"2005":266,"2006":271,"2007":272,"2008":273,"2009":274,"2010":275,"2011":276,"2012":277,"2013":278,"2014":279,"2015":280,"2016":281,"2017":282,"2018":283,"2019":284,"2020":285,"2021":286,"2022":287,"2023":288},0.06,1.47,0.22,0.25,0.33,0.48,0.79,1.04,0.77,0.9,1.48,1.3,1.7,1.05,1.86,1.72,5.41,9.55,2.41,2.88,1.95,2.52,3.14,1.35,2.5,2.36,1.79,2.96,1.61,0.2,{"impactFactor":20,"impactFactorByYear":20,"i10Index":290,"i10IndexLast5Year":223,"totalPublication":291,"totalPublicationByYear":292,"totalCitation":297,"totalCitationByYear":298,"totalCitationPerPublication":313,"totalCitationPerPublicationByYear":314,"hindexLast5Year":221,"hindex":293},42,1244,{"0":97,"1979":241,"1980":222,"1981":222,"1982":293,"1983":293,"1984":224,"1985":224,"1986":223,"1987":224,"1988":148,"1989":235,"1990":222,"1991":224,"1992":224,"1993":228,"1994":97,"1995":227,"1996":165,"1997":227,"1998":226,"1999":229,"2000":235,"2001":226,"2002":229,"2003":226,"2004":228,"2005":227,"2006":226,"2007":294,"2008":233,"2009":235,"2010":227,"2011":218,"2012":295,"2013":227,"2014":235,"2015":242,"2016":218,"2017":296,"2018":165,"2019":235,"2020":165,"2021":227,"2022":234,"2023":225,"2024":228,"2025":226,"2026":233},16,47,41,32,2194,{"1997":221,"1998":299,"1999":221,"2000":240,"2001":240,"2002":221,"2003":299,"2004":222,"2005":224,"2006":241,"2007":227,"2008":231,"2009":144,"2010":226,"2011":233,"2012":300,"2013":301,"2014":302,"2015":256,"2016":303,"2017":303,"2018":304,"2019":305,"2020":306,"2021":307,"2022":308,"2023":309,"2024":310,"2025":311,"2026":312},10,54,64,62,93,123,118,122,168,159,177,205,255,154,1.76,{"1997":315,"1998":316,"1999":317,"2000":318,"2001":214,"2002":317,"2003":316,"2004":319,"2005":320,"2006":211,"2007":321,"2008":322,"2009":323,"2010":324,"2011":325,"2012":326,"2013":327,"2014":328,"2015":329,"2016":330,"2017":331,"2018":332,"2019":333,"2020":334,"2021":145,"2022":335,"2023":336,"2024":337,"2025":338,"2026":339},0.43,0.4,0.55,0.35,0.63,0.68,0.6,0.69,0.42,0.89,1.52,1.32,2.29,2.38,1.93,4.04,2.91,4.24,4.54,4.21,4.3,8.85,7.59,10.2,4.4,{"id":341,"createTime":342,"updateTime":112,"relativeEntities":343,"slug":344,"properties":345,"entityType":18,"verifyStatus":127,"verifyTime":355,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":97,"subjectFields":356,"manageAffiliations":357,"indexDatabases":358,"url":367,"thumbnailPath":20,"statistic":368,"gsStatistic":384,"type":104,"analyzePriority":20},"b5209d2b-2258-40ef-8732-874e80fe24a5","2023-08-01T04:13:30.887+00:00",[],"VNU-Journal-of-Science-Medical-and-Pharmaceutical-Sciences",{"country":346,"eissn":347,"issn":349,"title":351,"gsId":353},{"VOID":117},{"VOID":348},"25881132",{"VOID":350},"26159309",{"EN":352},"VNU Journal of Science: Medical and Pharmaceutical Sciences",{"VOID":354},"nxupvWQAAAAJ","2023-08-01T04:16:22.633+00:00",[],[],[359],{"id":360,"indexDatabase":361,"url":366,"indexYears":20,"academicFieldIds":20,"indexDatabaseRanking":20},"1c684ac3-c7bf-4466-8841-3c6146083c3c",{"id":184,"createTime":20,"updateTime":20,"relativeEntities":362,"label":363,"description":364,"key":190,"publicationTags":365,"standard":20},[],{"EN":187,"VI":187},{"EN":189,"VI":189},[192],"https:\u002F\u002Fasean-cites.org\u002Fjournal_info?jid=11969","https:\u002F\u002Fjs.vnu.edu.vn\u002FMPS",{"impactFactor":21,"impactFactorByYear":369,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":370,"totalPublicationByYear":371,"totalCitation":376,"totalCitationByYear":377,"totalCitationPerPublication":378,"totalCitationPerPublicationByYear":379,"hindexLast5Year":142,"hindex":142},{"2019":202,"2020":206,"2021":200,"2022":200,"2023":205,"2024":204},360,{"2016":235,"2017":372,"2018":165,"2019":242,"2020":373,"2021":294,"2022":374,"2023":375,"2024":294},34,48,49,50,163,{"2016":240,"2017":240,"2018":230,"2019":235,"2020":147,"2021":230,"2022":223,"2023":145},0.45,{"2016":318,"2017":213,"2018":380,"2019":381,"2020":382,"2021":378,"2022":383,"2023":200},0.72,0.87,1.1,0.37,{"impactFactor":20,"impactFactorByYear":20,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":231,"totalPublicationByYear":385,"totalCitation":222,"totalCitationByYear":386,"totalCitationPerPublication":387,"totalCitationPerPublicationByYear":388,"hindexLast5Year":100,"hindex":101},{"0":100,"2014":99,"2015":99,"2016":225},{"2016":99,"2019":100,"2021":100,"2023":142,"2024":101,"2025":99,"2026":99},0.71,{"2016":202},{"id":390,"createTime":391,"updateTime":112,"relativeEntities":392,"slug":393,"properties":394,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":148,"subjectFields":404,"manageAffiliations":405,"indexDatabases":406,"url":407,"thumbnailPath":20,"statistic":408,"gsStatistic":443,"type":104,"analyzePriority":20},"e7ce3904-ad2d-4341-b39e-98ebe8da5908","2023-06-13T10:30:04.853+00:00",[],"Communications-in-Physics",{"country":395,"eissn":396,"issn":398,"title":400,"gsId":402},{"VOID":117},{"VOID":397},"28155947",{"VOID":399},"08863166",{"EN":401},"Communications in Physics",{"VOID":403},"FStER9AAAAAJ",[],[],[],"https:\u002F\u002Fvjs.ac.vn\u002Findex.php\u002Fcip",{"impactFactor":21,"impactFactorByYear":409,"i10Index":293,"i10IndexLast5Year":142,"totalPublication":415,"totalPublicationByYear":416,"totalCitation":420,"totalCitationByYear":421,"totalCitationPerPublication":429,"totalCitationPerPublicationByYear":430,"hindexLast5Year":221,"hindex":221},{"2008":206,"2009":410,"2010":259,"2011":411,"2012":411,"2013":208,"2014":412,"2015":201,"2016":204,"2017":212,"2018":412,"2019":149,"2020":413,"2021":378,"2022":414,"2023":212,"2024":316},0.3,0.03,0.16,0.34,0.28,738,{"2007":417,"2008":240,"2009":240,"2010":231,"2011":234,"2012":418,"2013":233,"2014":245,"2015":165,"2016":245,"2017":419,"2018":237,"2019":147,"2020":295,"2021":236,"2022":246,"2023":244,"2024":372,"2025":100},14,107,56,947,{"2007":242,"2008":146,"2009":146,"2010":222,"2011":422,"2012":249,"2013":372,"2014":423,"2015":300,"2016":424,"2017":425,"2018":426,"2019":427,"2020":428,"2021":222,"2022":227,"2023":242},52,94,86,129,76,91,106,1.28,{"2007":431,"2008":432,"2009":432,"2010":387,"2011":433,"2012":434,"2013":435,"2014":436,"2015":273,"2016":326,"2017":437,"2018":438,"2019":274,"2020":439,"2021":440,"2022":441,"2023":442},2.14,0.78,1.41,0.83,0.97,1.45,2.3,2.11,2.59,0.44,0.65,0.75,{"impactFactor":20,"impactFactorByYear":20,"i10Index":228,"i10IndexLast5Year":240,"totalPublication":444,"totalPublicationByYear":445,"totalCitation":449,"totalCitationByYear":450,"totalCitationPerPublication":457,"totalCitationPerPublicationByYear":458,"hindexLast5Year":240,"hindex":417},1117,{"0":145,"1972":99,"1991":222,"1992":148,"1993":146,"1994":144,"1995":417,"1996":101,"1997":99,"1998":241,"1999":241,"2000":299,"2001":144,"2002":223,"2003":231,"2004":227,"2005":231,"2006":242,"2007":236,"2008":243,"2009":446,"2010":447,"2011":290,"2012":302,"2013":374,"2014":448,"2015":244,"2016":422,"2017":232,"2018":237,"2019":419,"2020":246,"2021":234,"2022":234,"2023":237,"2024":242,"2025":97,"2026":227},33,44,92,1611,{"2004":143,"2005":451,"2006":144,"2007":144,"2008":221,"2009":235,"2010":165,"2011":97,"2012":97,"2013":97,"2014":302,"2015":447,"2016":295,"2017":374,"2018":255,"2019":452,"2020":306,"2021":425,"2022":306,"2023":453,"2024":454,"2025":455,"2026":456},8,85,153,178,188,132,1.44,{"2004":459,"2005":263,"2006":383,"2007":414,"2008":213,"2009":265,"2010":460,"2011":461,"2012":462,"2013":319,"2014":463,"2015":382,"2016":265,"2017":464,"2018":465,"2019":325,"2020":466,"2021":467,"2022":468,"2023":469,"2024":470,"2025":471,"2026":472},0.18,0.66,0.74,0.5,0.67,1.29,1.89,2.84,3.49,3.3,4.25,5.93,6.06,4.71,{"id":474,"createTime":475,"updateTime":476,"relativeEntities":477,"slug":478,"properties":479,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":20,"languages":488,"translateLanguages":20,"viewCount":222,"subjectFields":489,"manageAffiliations":490,"indexDatabases":498,"url":512,"thumbnailPath":20,"statistic":513,"gsStatistic":540,"type":104,"analyzePriority":20},"2300fd63-13a8-4ee9-92b0-d24d9e616c6b","2023-05-29T12:05:31.684+00:00","2026-08-27T01:57:29.561+00:00",[],"Journal-of-Computer-Science-and-Cybernetics",{"country":480,"issn":481,"title":483,"gsId":486},{"VOID":117},{"VOID":482},"18139663",{"EN":484,"VI":485},"Journal of Computer Science and Cybernetics","Tạp chí tin học và điều khiển học",{"VOID":487},"hVh9fuMAAAAJ",[130,131],[],[491],{"id":169,"createTime":20,"updateTime":20,"relativeEntities":492,"slug":20,"properties":493,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":178,"parentIds":497,"statistic":20},[],{"title":494,"country":495,"abbreviation":496},{"EN":173,"VI":174},{"VOID":117},{"VOID":177},[],[499],{"id":500,"indexDatabase":501,"url":506,"indexYears":507,"academicFieldIds":508,"indexDatabaseRanking":20},"0c897c2c-8ca4-4a7a-91b9-14955abc3043",{"id":184,"createTime":20,"updateTime":20,"relativeEntities":502,"label":503,"description":504,"key":190,"publicationTags":505,"standard":20},[],{"EN":187,"VI":187},{"EN":189,"VI":189},[192],"https:\u002F\u002Fasean-cites.org\u002Fjournal_info?jid=11305","2019-2021",[196,509,510,511],"a24a4497-b6ac-43f3-ae94-c044be819e49","b2d37900-0c9f-4074-a519-9ee0b570caa7","37da756c-1c5e-4925-87f2-a9bd3ce5859c","http:\u002F\u002Fvjs.ac.vn\u002Findex.php\u002Fjcc",{"impactFactor":21,"impactFactorByYear":514,"i10Index":224,"i10IndexLast5Year":101,"totalPublication":519,"totalPublicationByYear":520,"totalCitation":525,"totalCitationByYear":526,"totalCitationPerPublication":532,"totalCitationPerPublicationByYear":533,"hindexLast5Year":417,"hindex":417},{"2013":203,"2014":203,"2015":207,"2016":459,"2017":203,"2018":515,"2019":213,"2020":516,"2021":321,"2022":517,"2023":462,"2024":518},0.04,0.32,0.39,0.57,1184,{"2012":521,"2013":452,"2014":372,"2015":522,"2016":523,"2017":148,"2018":524,"2019":242,"2020":225,"2021":231,"2022":293,"2023":227,"2024":101},473,71,251,134,995,{"2012":527,"2013":528,"2014":528,"2015":427,"2016":529,"2017":530,"2018":531,"2019":305,"2020":375,"2021":528,"2022":221,"2023":246},149,45,114,51,232,0.84,{"2012":516,"2013":534,"2014":326,"2015":429,"2016":378,"2017":535,"2018":536,"2019":537,"2020":283,"2021":538,"2022":442,"2023":539},0.53,3.4,1.73,3.93,1.88,1.54,{"impactFactor":20,"impactFactorByYear":20,"i10Index":244,"i10IndexLast5Year":227,"totalPublication":541,"totalPublicationByYear":542,"totalCitation":543,"totalCitationByYear":544,"totalCitationPerPublication":286,"totalCitationPerPublicationByYear":554,"hindexLast5Year":148,"hindex":293},1105,{"0":144,"1981":99,"1985":293,"1986":230,"1987":231,"1988":417,"1989":221,"1990":293,"1991":222,"1992":221,"1993":144,"1994":224,"1995":225,"1996":227,"1997":237,"1998":242,"1999":295,"2000":290,"2001":447,"2002":447,"2003":446,"2004":227,"2005":226,"2006":242,"2007":97,"2008":228,"2009":226,"2010":234,"2011":295,"2012":375,"2013":237,"2014":296,"2015":165,"2016":235,"2017":231,"2018":235,"2019":229,"2020":229,"2021":228,"2022":229,"2023":229,"2024":231,"2025":146},3272,{"2007":240,"2008":417,"2009":143,"2010":145,"2011":224,"2012":242,"2013":235,"2014":165,"2015":246,"2016":254,"2017":256,"2018":545,"2019":546,"2020":547,"2021":548,"2022":549,"2023":550,"2024":551,"2025":552,"2026":553},109,173,236,318,398,469,442,440,297,{"2007":555,"2008":211,"2009":288,"2010":412,"2011":556,"2012":321,"2013":380,"2014":557,"2015":269,"2016":558,"2017":559,"2018":560,"2019":561,"2020":562,"2021":563,"2022":564,"2023":565,"2024":566,"2025":567},0.29,0.46,0.91,2.27,2.42,4.19,7.86,10.73,11.78,18.09,21.32,18.42,62.86,{"id":569,"createTime":570,"updateTime":476,"relativeEntities":571,"slug":572,"properties":573,"entityType":18,"verifyStatus":127,"verifyTime":585,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":296,"subjectFields":586,"manageAffiliations":587,"indexDatabases":603,"url":604,"thumbnailPath":20,"statistic":605,"gsStatistic":619,"type":104,"analyzePriority":20},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":574,"issn":575,"title":577,"introduce":580,"gsId":583},{"VOID":117},{"VOID":576},"23541210",{"EN":578,"VI":579},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"EN":581,"VI":582},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"VOID":584},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",[],[588],{"id":589,"createTime":20,"updateTime":20,"relativeEntities":590,"slug":20,"properties":591,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":601,"parentIds":602,"statistic":20},"6413896b-eca9-442b-a73f-182a58a0ce40",[],{"title":592,"address":595,"country":598,"abbreviation":599},{"EN":593,"VI":594},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"EN":596,"VI":597},"No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam","Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam",{"VOID":117},{"VOID":600},"ctump","http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":21,"impactFactorByYear":606,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":608,"totalPublicationByYear":609,"totalCitation":614,"totalCitationByYear":615,"totalCitationPerPublication":204,"totalCitationPerPublicationByYear":617,"hindexLast5Year":142,"hindex":142},{"2022":607,"2023":207,"2024":202},0.01,1556,{"2020":144,"2021":610,"2022":611,"2023":612,"2024":613,"2025":218},57,306,801,358,161,{"2021":241,"2022":374,"2023":616},99,{"2021":618,"2022":412,"2023":200},0.23,{"impactFactor":20,"impactFactorByYear":20,"i10Index":100,"i10IndexLast5Year":100,"totalPublication":620,"totalPublicationByYear":621,"totalCitation":620,"totalCitationByYear":622,"totalCitationPerPublication":99,"totalCitationPerPublicationByYear":625,"hindexLast5Year":146,"hindex":146},476,{"0":299,"2019":100,"2021":234,"2022":553,"2023":545,"2024":451,"2025":146,"2026":145},{"2021":101,"2022":100,"2023":255,"2024":623,"2025":454,"2026":624},136,83,{"2021":201,"2022":607,"2023":626,"2024":222,"2025":627,"2026":628},0.62,25.43,13.83,{"id":630,"createTime":631,"updateTime":476,"relativeEntities":632,"slug":633,"properties":634,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":20,"languages":646,"translateLanguages":20,"viewCount":228,"subjectFields":647,"manageAffiliations":648,"indexDatabases":649,"url":650,"thumbnailPath":651,"statistic":652,"gsStatistic":688,"type":104,"analyzePriority":20},"6984a56a-db70-403b-9cc4-4013e1ceaffa","2023-05-09T06:47:40.346+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Nghi%C3%AAn%20c%E1%BB%A9u%20n%C6%B0%E1%BB%9Bc%20ngo%C3%A0i",{"country":635,"issn":636,"title":638,"introduce":641,"gsId":644},{"VOID":117},{"VOID":637},"25252445",{"EN":639,"VI":640},"VNU Journal of Foreign Studies","Tạp chí Nghiên cứu nước ngoài",{"EN":642,"VI":643},"{\"ops\":[{\"insert\":\"\\n\\nThe \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"VNU Journal of Science\"},{\"insert\":\"\\n was established in 1985 for the publication of national and international research papers in all fields of natural sciences and technology, social sciences and humanities. Since then, the journal has grown in quality, size and scope and now comprises a dozen of serials spanning academic research. In 2002, with the rapid expansion of the field of Foreign Languages and International Studies, the \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"VNU Journal of Science\"},{\"insert\":\"\\n was delighted to announce the launch of the \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"VNU Journal of Science: Foreign Studies\"},{\"insert\":\"\\n.\\n\\n\\nSince 2017, as a natural development from its predecessor \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"VNU Journal of Science: Foreign Studies\"},{\"insert\":\"\\n, the\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\" \"},{\"attributes\":{\"italic\":true,\"bold\":true},\"insert\":\"VNU Journal of Foreign Studies \"},{\"insert\":\"\\ncontinues to be an official, independent publication of the University of Languages and International Studies (ULIS) under Vietnam National University (VNU).\\nThe\\n\"},{\"attributes\":{\"italic\":true,\"bold\":true},\"insert\":\" VNU Journal of Foreign Studies\"},{\"attributes\":{\"italic\":true},\"insert\":\" \"},{\"insert\":\"\\npublishes \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"blind\"},{\"insert\":\"\\n \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"peer-reviewed\"},{\"insert\":\"\\n research papers, discussions and reviews concerning:\\nLinguisticsForeign language educationInternational studiesRelated social sciences and humanities\\nBimonthly in 4 English editions and 2 Vietnamese editions in the current year in both print and electronic forms, the journal provides maximum exposure for published articles, making research available to all to read and share.\\n\\n\\n\"}]}","{\"ops\":[{\"attributes\":{\"italic\":true},\"insert\":\"Tạp chí Khoa học, Đại học Quốc gia Hà Nội\"},{\"insert\":\"\\n được thành lập năm 1985 với mục đích xuất bản các bài báo nghiên cứu trong nước và quốc tế về tất cả các lĩnh vực khoa học tự nhiên và công nghệ, khoa học xã hội và nhân văn. Kể từ đó, tạp chí đã phát triển về chất lượng, quy mô và phạm vi với hàng chục số báo liên quan đến nghiên cứu học thuật. Năm 2002, với sự phát triển nhanh chóng của lĩnh vực Ngoại ngữ và Quốc tế học, \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"Tạp chí Khoa học Đại học Quốc gia Hà Nội\"},{\"insert\":\"\\n đã vui mừng thông báo ra mắt Chuyên san \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"Nghiên cứu Nước ngoài.\"},{\"insert\":\"\\n\\n\\nKể từ năm 2017, như một sự kế thừa và phát triển từ tiền thân Chuyên san \\n\"},{\"attributes\":{\"italic\":true},\"insert\":\"Nghiên cứu Nước ngoài\"},{\"insert\":\"\\n của Tạp chí Khoa học, Đại học Quốc gia Hà Nội, \\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tạp chí\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\" \"},{\"insert\":\"\\n\"},{\"attributes\":{\"italic\":true,\"bold\":true},\"insert\":\"Nghiên cứu nước ngoài \"},{\"insert\":\"\\ntiếp tục là ấn phẩm khoa học chính thức và độc lập của Trường Đại học Ngoại ngữ, Đại học Quốc gia Hà Nội.\\nTạp chí \\n\"},{\"attributes\":{\"italic\":true,\"bold\":true},\"insert\":\"Nghiên cứu nước ngoài\"},{\"insert\":\"\\n xuất bản các bài báo nghiên cứu, trao đổi và đánh giá đã được phản biện kín về:\\nNgôn ngữ họcGiảng dạy ngoại ngữ\u002Fngôn ngữQuốc tế họcCác ngành khoa học xã hội và nhân văn có liên quan\\nTạp chí xuất bản định kì 06 số\u002Fnăm (gồm 04 số tiếng Anh\u002Fnăm và 2 số tiếng Việt\u002Fnăm) dưới dạng bản in và bản điện tử. Tạp chí cung cấp khả năng tiếp cận tối đa tới các bài báo đã xuất bản nhằm giúp độc giả dễ dàng đọc và chia sẻ.\\n\"}]}",{"VOID":645},"jyihv3YAAAAJ",[130,131],[],[],[],"https:\u002F\u002Fjfs.ulis.vnu.edu.vn\u002Findex.php\u002Ffs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6984a56a-db70-403b-9cc4-4013e1ceaffa\u002F92693604f5caf63c64520c5c2cd756b5.jpg",{"impactFactor":21,"impactFactorByYear":653,"i10Index":654,"i10IndexLast5Year":299,"totalPublication":655,"totalPublicationByYear":656,"totalCitation":662,"totalCitationByYear":663,"totalCitationPerPublication":673,"totalCitationPerPublicationByYear":674,"hindexLast5Year":235,"hindex":235},{"2007":411,"2010":208,"2011":205,"2012":515,"2013":259,"2014":515,"2015":515,"2016":207,"2017":212,"2018":200,"2019":205,"2020":414,"2021":378,"2022":262,"2023":212,"2024":204},67,1200,{"2002":148,"2003":148,"2004":144,"2005":446,"2006":237,"2007":226,"2008":97,"2009":234,"2010":372,"2011":233,"2012":165,"2013":300,"2014":232,"2015":165,"2016":290,"2017":657,"2018":303,"2019":658,"2020":659,"2021":660,"2022":624,"2023":661,"2024":522,"2025":375},130,78,90,80,61,3204,{"2002":101,"2003":100,"2004":100,"2005":664,"2006":144,"2007":222,"2008":665,"2009":666,"2010":290,"2011":667,"2012":225,"2013":654,"2014":668,"2015":243,"2016":419,"2017":669,"2018":670,"2019":671,"2020":672,"2021":547,"2022":300,"2023":299,"2025":148},189,223,765,246,98,171,377,355,199,2.67,{"2002":288,"2003":212,"2004":459,"2005":675,"2006":676,"2007":320,"2008":677,"2009":678,"2010":679,"2011":680,"2012":322,"2013":679,"2014":681,"2015":682,"2016":683,"2017":326,"2018":684,"2019":685,"2020":686,"2021":687,"2022":441,"2023":412,"2025":410},5.73,0.31,7.19,20.68,1.24,7.03,2.58,1.59,1.33,4.05,4.55,2.21,2.95,{"impactFactor":20,"impactFactorByYear":20,"i10Index":689,"i10IndexLast5Year":690,"totalPublication":691,"totalPublicationByYear":692,"totalCitation":703,"totalCitationByYear":704,"totalCitationPerPublication":719,"totalCitationPerPublicationByYear":720,"hindexLast5Year":237,"hindex":246},379,311,2120,{"0":455,"1960":99,"1971":99,"1975":99,"1987":99,"1988":99,"1989":99,"1990":142,"1992":99,"1993":99,"1994":143,"1995":143,"1996":142,"1997":101,"1998":146,"1999":101,"2000":100,"2001":101,"2002":145,"2003":143,"2004":240,"2005":226,"2006":148,"2007":226,"2008":230,"2009":241,"2010":222,"2011":218,"2012":242,"2013":446,"2014":295,"2015":243,"2016":693,"2017":694,"2018":695,"2019":303,"2020":696,"2021":697,"2022":698,"2023":699,"2024":700,"2025":701,"2026":702},77,75,97,143,167,156,182,231,230,128,13225,{"2003":243,"2004":244,"2005":295,"2006":290,"2007":251,"2008":530,"2009":422,"2010":705,"2011":706,"2012":427,"2013":616,"2014":707,"2015":614,"2016":708,"2017":709,"2018":710,"2019":711,"2020":712,"2021":713,"2022":714,"2023":715,"2024":716,"2025":717,"2026":718},74,88,146,228,310,347,413,636,944,1261,1400,1846,2511,1882,6.24,{"2003":721,"2004":722,"2005":723,"2006":724,"2007":280,"2008":725,"2009":142,"2010":726,"2011":727,"2012":728,"2013":101,"2014":729,"2015":730,"2016":286,"2017":731,"2018":732,"2019":722,"2020":733,"2021":734,"2022":735,"2023":736,"2024":737,"2025":738,"2026":739},9.2,4.44,1.64,2.8,2.43,4.35,3.83,3.03,3.56,3.5,4.13,3.58,4.45,5.65,8.08,7.69,7.99,10.92,14.7,{"id":741,"createTime":742,"updateTime":476,"relativeEntities":743,"slug":744,"properties":745,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":758,"languages":759,"translateLanguages":20,"viewCount":237,"subjectFields":760,"manageAffiliations":761,"indexDatabases":762,"url":771,"thumbnailPath":772,"statistic":773,"gsStatistic":793,"type":104,"analyzePriority":20},"21d239d8-ac9d-48c7-a176-9d8aadc5eba5","2023-08-21T02:43:48.721+00:00",[],"Khoa-h%E1%BB%8Dc-%C4%90HQGHN-Khoa-h%E1%BB%8Dc-T%E1%BB%B1-nhi%C3%AAn-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87",{"country":746,"eissn":747,"issn":749,"title":751,"introduce":754,"gsId":756},{"VOID":117},{"VOID":748},"25881140",{"VOID":750},"26159317",{"EN":752,"VI":753},"VNU Journal of Science: Natural Science and Technology","Khoa học ĐHQGHN: Khoa học Tự nhiên và Công nghệ",{"EN":755},"{\"ops\":[{\"insert\":\"The \"},{\"attributes\":{\"italic\":true},\"insert\":\"Journal\"},{\"insert\":\" \"},{\"attributes\":{\"italic\":true},\"insert\":\"of\"},{\"insert\":\" \"},{\"attributes\":{\"italic\":true},\"insert\":\"Science\"},{\"insert\":\" was established in 1985 for the publication of national and international research papers in all fields of natural sciences and technology, social sciences and humanities. Since then, the journal has grown in quality, size and scope and now comprises a dozen of serials spanning academic research.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"With the rapid expansion of the field of Economics, the VNU \"},{\"attributes\":{\"italic\":true},\"insert\":\"Journal\"},{\"insert\":\" \"},{\"attributes\":{\"italic\":true},\"insert\":\"of\"},{\"insert\":\" \"},{\"attributes\":{\"italic\":true},\"insert\":\"Science\"},{\"insert\":\" is delighted to announce the launch of the \"},{\"attributes\":{\"italic\":true},\"insert\":\"VNU Journal of Science: Natural Sciences and Technology (JS: NST) \"},{\"insert\":\"since 1985. This serial publication provides researchers with the opportunity to publish research covering aspects in these areas in the popular \"},{\"attributes\":{\"italic\":true},\"insert\":\"VNU Journal of Science\"},{\"insert\":\" series.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"As a fully open access publication, the journal will provide maximum exposure for published articles, making the research available to all to read and share. The journal will be published quarterly in March, June, September and December.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"JS: NST is an open access journal publishing double-blinded peer-reviewed research papers, communications and reviews dealing with Biology, Bio-technology, Chemistry, Chemical engineering, Energy, Environmental technology and Materials engineering.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Publication Ethics\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"VNUJS is committed to maintaining the highest standards of publication ethics and takes all possible measures against any publication malpractices. The journal follows the guidelines and recommendations of the Committee on Publication Ethics (C.O.P.E) to ensure ethical publishing practices.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Plagiarism is strictly prohibited and will not be tolerated. Any form of plagiarism, including but not limited to copying, paraphrasing, or reusing previously published work without proper attribution, will result in rejection of the manuscript and potential sanctions against the author. VNUJS utilizes DoIt as plagiarism detection software to verify the originality of submitted manuscripts.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"The publication ethics statement with full detail of the responsibilities of authors, reviewers and editors can be found \"},{\"attributes\":{\"bold\":true,\"color\":\"#464d50\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fjs.vnu.edu.vn\u002FNST\u002Fethics\"},\"insert\":\"here\"},{\"attributes\":{\"bold\":true},\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Peer Review Process\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Any manuscript followed the journal’s scope and author guideline will be assigned to the managing editors. All manuscripts have undergone editorial screening and anonymous double-blind peer-review by the at least one independent expert in the field. The managing editor makes an editorial decision, which is subject to endorsement by the Editor – in - Chief.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"The journal publishing process can be found in detail \"},{\"attributes\":{\"bold\":true,\"color\":\"#464d50\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fdrive.google.com\u002Ffile\u002Fd\u002F136BOGahfq9_5BB3TzSBsLBkQKfCUe5yN\u002Fview?usp=share_link\"},\"insert\":\"here\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"VOID":757},"ZfBridMAAAAJ","Admin update database",[130,131],[],[],[763],{"id":764,"indexDatabase":765,"url":770,"indexYears":20,"academicFieldIds":20,"indexDatabaseRanking":20},"6684da33-2cb9-49f9-8332-28f0bcd72e39",{"id":184,"createTime":20,"updateTime":20,"relativeEntities":766,"label":767,"description":768,"key":190,"publicationTags":769,"standard":20},[],{"EN":187,"VI":187},{"EN":189,"VI":189},[192],"https:\u002F\u002Fasean-cites.org\u002Fjournal_info?jid=11968","https:\u002F\u002Fjs.vnu.edu.vn\u002FNST","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F21d239d8-ac9d-48c7-a176-9d8aadc5eba5\u002Fb081d4211e382646c2cdc054ead551b3.jpg",{"impactFactor":21,"impactFactorByYear":774,"i10Index":225,"i10IndexLast5Year":99,"totalPublication":776,"totalPublicationByYear":777,"totalCitation":779,"totalCitationByYear":780,"totalCitationPerPublication":785,"totalCitationPerPublicationByYear":786,"hindexLast5Year":144,"hindex":144},{"2000":411,"2005":607,"2007":203,"2010":607,"2011":411,"2012":202,"2013":203,"2014":411,"2015":203,"2016":203,"2017":515,"2018":411,"2019":515,"2020":209,"2021":676,"2022":775,"2023":288,"2024":200},0.19,1700,{"1985":226,"1986":447,"1987":225,"1988":165,"1989":165,"1990":294,"1991":290,"1992":241,"1993":373,"1994":242,"1995":294,"1996":295,"1999":372,"2000":235,"2001":223,"2002":296,"2003":447,"2004":233,"2005":296,"2006":231,"2007":372,"2008":234,"2009":232,"2010":236,"2011":372,"2012":227,"2013":296,"2014":296,"2015":372,"2016":778,"2017":453,"2018":254,"2019":256,"2020":375,"2021":251,"2022":530,"2023":452,"2024":231,"2025":230},165,870,{"1995":100,"1999":100,"2001":142,"2002":225,"2003":99,"2004":100,"2005":101,"2007":165,"2008":781,"2009":446,"2010":782,"2011":232,"2012":222,"2013":144,"2014":143,"2015":241,"2016":425,"2017":783,"2018":425,"2019":784,"2020":447,"2021":661,"2022":225,"2023":451},82,60,55,102,0.51,{"1995":515,"1999":259,"2001":261,"2002":626,"2003":203,"2004":259,"2005":207,"2007":787,"2008":788,"2009":381,"2010":539,"2011":789,"2012":215,"2013":413,"2014":412,"2015":790,"2016":432,"2017":214,"2018":791,"2019":313,"2020":792,"2021":435,"2022":517,"2023":207},0.85,2.22,1.12,0.38,2.19,0.88,{"impactFactor":20,"impactFactorByYear":20,"i10Index":221,"i10IndexLast5Year":100,"totalPublication":664,"totalPublicationByYear":794,"totalCitation":795,"totalCitationByYear":796,"totalCitationPerPublication":797,"totalCitationPerPublicationByYear":798,"hindexLast5Year":143,"hindex":299},{"0":145,"1999":241,"2000":144,"2001":142,"2002":99,"2003":293,"2004":100,"2005":101,"2006":100,"2007":240,"2008":240,"2009":143,"2010":146,"2011":144,"2012":144,"2013":146,"2014":142,"2015":142,"2016":251,"2017":99},425,{"2008":101,"2009":451,"2010":144,"2011":148,"2012":293,"2013":230,"2014":417,"2015":148,"2016":372,"2017":165,"2018":165,"2019":232,"2020":237,"2021":235,"2022":242,"2023":218,"2024":296,"2025":230,"2026":221},2.25,{"2008":263,"2009":799,"2010":800,"2011":801,"2012":436,"2013":101,"2014":730,"2015":802,"2016":803,"2017":165},1.6,1.57,1.36,3.75,0.54,{"id":805,"createTime":806,"updateTime":476,"relativeEntities":807,"slug":808,"properties":809,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":758,"languages":20,"translateLanguages":20,"viewCount":244,"subjectFields":821,"manageAffiliations":822,"indexDatabases":823,"url":824,"thumbnailPath":825,"statistic":826,"gsStatistic":832,"type":104,"analyzePriority":20},"954132b5-ca74-461c-b819-45ad6e49a404","2023-08-17T03:30:52.301+00:00",[],"HPU2-Journal-of-Science-Natural-Sciences-and-Technology",{"country":810,"issn":811,"title":813,"introduce":816,"gsId":819},{"VOID":117},{"VOID":812},"28155637",{"EN":814,"VI":815},"HPU2 Journal of Science: Natural Sciences and Technology","TẠP CHÍ KHOA HỌC TRƯỜNG ĐHSP HÀ NỘI 2: CHUYÊN SAN KHOA HỌC TỰ NHIÊN VÀ CÔNG NGHỆ",{"EN":817,"VI":818},"{\"ops\":[{\"insert\":\"HPU2 journal of Science aims to provide an interdisciplinary platform for the dissemination of advances in sciences and technology. The journal publishes original papers of scientific or technological value in all areas of natural, social or educational sciences.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"The main interest of HPU2 Journal of Science: Natural sciences and technology is in papers that describe valuable findings in physics, mathematics, chemistry, biology; solving engineering or technological problems.\"},{\"attributes\":{\"align\":\"justify\",\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"insert\":\"The main interest of HPU2 Journal of Science: Social Sciences and Humanity is to facilitate the publication of high-quality papers in various areas of social sciences and studies for human development.\"},{\"attributes\":{\"align\":\"justify\",\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"insert\":\"The main interest of HPU2 Journal of Science: Educational Sciences is to publish papers in the field of educational sciences and applications of advances to education for improving and enhancing science education at all levels.\"},{\"attributes\":{\"align\":\"justify\",\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"insert\":\"Papers that are published by HPU2 Journal of Science are doubled-blind, peer-reviewed by at least two experts, are evaluated by the section editor and editor in chief.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Types of Articles\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Research articles\"},{\"attributes\":{\"align\":\"justify\",\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"insert\":\"Academic reports of original research that have never been published elsewhere in any languages. Manuscripts, where appropriate, should contain the following sections in the order: Title, Authors, Author affiliations, Email address of corresponding authors, Abstract, Keywords, Nomenclature (if any), Introduction, Experiment, Theory, Results and Discussion, Conclusions, Conflict of Interest, Acknowledgments (if any), References, Appendix (if any). Pre-published are to be formatted according to Templates (MS-Word version). \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Review articles\"},{\"attributes\":{\"align\":\"justify\",\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"insert\":\"In addition to invited reviews, literature reviews, systematic reviews, and critical reviews will be accepted for consideration. The manuscript should be composed and organized according to the required sequence: Titles, Author names, Affiliations, Email addresses, Abstract, Keywords, Main text, Conclusion, Conflict of Interest, Acknowledgments (if any), References. Although, the main text structure may vary based on the review subtopics, the articles should be formatted according to suitable Templates as research articles.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Khoa học Trường ĐHSP Hà Nội 2 nhằm mục đích cung cấp một nền tảng liên ngành của sự phổ biến những tiến bộ của khoa học và công nghệ. Tạp chí xuất bản các bài báo gốc có giá trị khoa học hoặc công nghệ trong tất cả các lĩnh vực khoa học tự nhiên, xã hội hoặc giáo dục.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Chuyên san Khoa học tự nhiên và công nghệ:\"},{\"insert\":\" Là các bài báo mô tả những phát hiện có giá trị trong vật lý, toán học, hóa học, sinh học; giải quyết các vấn đề kỹ thuật hoặc công nghệ.\"},{\"attributes\":{\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Chuyên san Khoa học Xã hội và Nhân văn:\"},{\"insert\":\" là các bài báo xuất bản chất lượng cao trong các lĩnh vực khác nhau của khoa học xã hội và nghiên cứu phát triển con người.\"},{\"attributes\":{\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Chuyên san Khoa học giáo dục:\"},{\"insert\":\" là các bài báo xuất bản trong lĩnh vực khoa học giáo dục và các ứng dụng của tiến bộ vào giáo dục để cải thiện và nâng cao giáo dục khoa học ở tất cả các cấp.\"},{\"attributes\":{\"list\":\"bullet\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí trường ĐHSP Hà Nội 2 xuất bản được phản biện kín, xét duyệt bởi ít nhất 02 chuyên gia, và được đánh giá, chọn lựa từ ban biên tập và Tổng biên tập.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Các loại bài báo\"},{\"insert\":\":\\nBài báo nghiên cứu:\"},{\"attributes\":{\"list\":\"ordered\"},\"insert\":\"\\n\"},{\"insert\":\"Báo cáo học thuật về nghiên cứu ban đầu chưa từng được xuất bản ở bất kỳ nơi nào, hay bằng bất kỳ ngôn ngữ nào khác. Bản thảo thích hợp, nên chứa các phần sau theo thứ tự: Tiêu đề, Tác giả, Liên kết tác giả, Địa chỉ email của tác giả tương ứng, Tóm tắt, Từ khóa, Danh pháp (nếu có), Giới thiệu, Thử nghiệm, Lý thuyết, Kết quả và thảo luận, Kết luận, Xung đột quan tâm, Lời cảm ơn (nếu có), Tài liệu tham khảo, Phụ lục (nếu có). Bản xuất bản trước phải được định dạng theo Mẫu (phiên bản MS-Word).\\n2. Bài báo tổng quan:\\nNgoài các bài phê bình được mời, các bài phê bình tài liệu, bài phê bình có hệ thống và bài phê bình sẽ được chấp nhận để xem xét. Bản thảo cần được soạn thảo và sắp xếp theo trình tự yêu cầu: Tên sách, Tên tác giả, Liên kết, Địa chỉ email, Tóm tắt, Từ khóa, Nội dung chính, Kết luận, Xung đột lợi ích, Lời cảm ơn (nếu có), Tài liệu tham khảo. Mặc dù, cấu trúc văn bản chính có thể thay đổi dựa trên các chủ đề phụ của bài đánh giá, các bài báo nên được định dạng theo các Mẫu phù hợp như các bài báo nghiên cứu.\\n\"}]}",{"VOID":820},"YPoBvsIAAAAJ",[],[],[],"https:\u002F\u002Fsj.hpu2.edu.vn\u002Findex.php\u002Fjournal","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F954132b5-ca74-461c-b819-45ad6e49a404\u002F2790ef1d0a7d7a40a504c2fc1647f670.jpg",{"impactFactor":21,"impactFactorByYear":827,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":423,"totalPublicationByYear":829,"totalCitation":229,"totalCitationByYear":830,"totalCitationPerPublication":618,"totalCitationPerPublicationByYear":831,"hindexLast5Year":100,"hindex":100},{"2024":828},0.17,{"2022":231,"2023":372,"2024":237},{"2022":451,"2023":221,"2024":100},{"2022":263,"2023":318,"2024":259},{"impactFactor":20,"impactFactorByYear":20,"i10Index":142,"i10IndexLast5Year":142,"totalPublication":424,"totalPublicationByYear":833,"totalCitation":248,"totalCitationByYear":834,"totalCitationPerPublication":835,"totalCitationPerPublicationByYear":836,"hindexLast5Year":143,"hindex":143},{"0":100,"2022":229,"2023":231,"2024":165,"2025":240},{"2023":143,"2024":231,"2025":295,"2026":372},1.22,{"2023":209,"2024":434,"2025":837},4.56,{"id":839,"createTime":840,"updateTime":841,"relativeEntities":842,"slug":843,"properties":844,"entityType":18,"verifyStatus":127,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":165,"subjectFields":856,"manageAffiliations":857,"indexDatabases":865,"url":905,"thumbnailPath":20,"statistic":906,"gsStatistic":938,"type":104,"analyzePriority":20},"21ccdb34-414d-420f-8a60-a592a2fa848e","2023-05-29T10:42:53.358+00:00","2026-08-27T01:57:29.560+00:00",[],"Vietnam-Journal-of-Earth-Sciences",{"country":845,"eissn":846,"issn":848,"title":850,"introduce":852,"gsId":854},{"VOID":117},{"VOID":847},"26159783",{"VOID":849},"08667187",{"EN":851},"Vietnam Journal of Earth Sciences",{"EN":853},"Science of the Earth, formerly Vietnam Journal of Earth Sciences, is a peer-reviewed journal to publish high-quality articles on the entire range of earth sciences and the environment, focused on the Asia Pacific region and their correlations and connections to the globe. The journal publishes fundamental and applied research in earth sciences and the environment, including geology, geophysics, geography, soil science, hydrology, meteorology, oceanography, petroleum, geohazards, environmental sciences, environmental engineering, sustainable development, geoinformatics, geodesy, GIS, and remote sensing.",{"VOID":855},"5htfr3YAAAAJ",[],[858],{"id":169,"createTime":20,"updateTime":20,"relativeEntities":859,"slug":20,"properties":860,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":178,"parentIds":864,"statistic":20},[],{"title":861,"country":862,"abbreviation":863},{"EN":173,"VI":174},{"VOID":117},{"VOID":177},[],[866,878,889],{"id":867,"indexDatabase":868,"url":873,"indexYears":874,"academicFieldIds":875,"indexDatabaseRanking":877},"6ace2085-a177-4a27-b309-8813b832111e",{"id":78,"createTime":20,"updateTime":20,"relativeEntities":869,"label":870,"description":871,"key":84,"publicationTags":872,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],"https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21101039869","2018-2024",[876],"1689391c-5702-4349-aaa7-d720ee4321fc","NONE",{"id":879,"indexDatabase":880,"url":885,"indexYears":886,"academicFieldIds":887,"indexDatabaseRanking":20},"dadb15a8-ee22-41c2-a287-49e969d9a998",{"id":184,"createTime":20,"updateTime":20,"relativeEntities":881,"label":882,"description":883,"key":190,"publicationTags":884,"standard":20},[],{"EN":187,"VI":187},{"EN":189,"VI":189},[192],"https:\u002F\u002Fasean-cites.org\u002Fjournal_info?jid=10629","2016-2022",[888],"e04f14cf-280b-4aa8-b711-b77ddd79cbaf",{"id":890,"indexDatabase":891,"url":902,"indexYears":20,"academicFieldIds":903,"indexDatabaseRanking":20},"06f278ee-37b9-41eb-a9b0-3d2d77fa502b",{"id":892,"createTime":20,"updateTime":20,"relativeEntities":893,"label":894,"description":896,"key":899,"publicationTags":900,"standard":20},"88bab0f7-443b-476c-a72a-7fa5222da393",[],{"EN":895,"VI":895},"ISI\u002FESCI  - Emerging Sources Citation Index",{"EN":897,"VI":898},"ESCI database","Cơ sở dữ liệu ESCI","esci",[901,70],"ESCI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0866-7187",[904],"0db73426-2364-455f-81a4-efe0f91d712e","https:\u002F\u002Fvjs.ac.vn\u002Findex.php\u002Fjse\u002F",{"impactFactor":21,"impactFactorByYear":907,"i10Index":245,"i10IndexLast5Year":227,"totalPublication":912,"totalPublicationByYear":913,"totalCitation":915,"totalCitationByYear":916,"totalCitationPerPublication":926,"totalCitationPerPublicationByYear":927,"hindexLast5Year":224,"hindex":224},{"2007":607,"2008":607,"2010":607,"2011":203,"2012":607,"2013":607,"2014":411,"2015":203,"2016":151,"2017":262,"2018":316,"2019":908,"2020":909,"2021":465,"2022":539,"2023":910,"2024":911},1.03,1.08,1.49,1.43,1180,{"2000":783,"2001":782,"2002":375,"2003":254,"2004":373,"2005":419,"2006":610,"2007":232,"2008":294,"2009":256,"2010":530,"2011":914,"2012":528,"2013":783,"2014":374,"2015":246,"2016":244,"2017":242,"2018":446,"2019":97,"2020":246,"2021":165,"2022":242,"2023":374,"2024":234,"2025":142},79,2421,{"2000":299,"2001":148,"2002":240,"2003":241,"2004":221,"2005":148,"2006":225,"2007":223,"2008":222,"2009":246,"2010":218,"2011":232,"2012":661,"2013":294,"2014":917,"2015":781,"2016":918,"2017":919,"2018":920,"2019":921,"2020":922,"2021":923,"2022":924,"2023":925,"2024":240,"2025":99},73,197,219,380,281,328,148,183,160,2.05,{"2000":459,"2001":262,"2002":459,"2003":261,"2004":262,"2005":217,"2006":318,"2007":928,"2008":214,"2009":461,"2010":378,"2011":264,"2012":801,"2013":787,"2014":910,"2015":929,"2016":930,"2017":931,"2018":932,"2019":933,"2020":934,"2021":935,"2022":936,"2023":937,"2024":149,"2025":262},0.47,1.91,4.93,7.3,11.52,9.06,7.63,5.1,6.1,3.27,{"impactFactor":20,"impactFactorByYear":20,"i10Index":529,"i10IndexLast5Year":249,"totalPublication":225,"totalPublicationByYear":939,"totalCitation":940,"totalCitationByYear":941,"totalCitationPerPublication":948,"totalCitationPerPublicationByYear":949,"hindexLast5Year":231,"hindex":228},{"1017":99,"2015":99,"2016":100,"2017":101,"2018":101,"2019":99,"2020":142,"2022":100,"2023":100,"2024":99},3528,{"2014":417,"2015":235,"2016":295,"2017":252,"2018":616,"2019":707,"2020":942,"2021":943,"2022":795,"2023":944,"2024":945,"2025":946,"2026":947},280,403,436,525,589,366,176.4,{"2015":235,"2016":950,"2017":229,"2018":446,"2019":707,"2020":253,"2022":951,"2023":952,"2024":945},20.5,212.5,218,{"meta":954,"data":956},{"total":955},"2526",[957,1121,1251,1500,1667,1855,1975,2303,2484,2616],{"id":958,"createTime":959,"updateTime":960,"relativeEntities":961,"slug":962,"properties":963,"entityType":972,"verifyStatus":127,"verifyTime":973,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":975,"fullTextUrl":20,"authors":976,"publicationType":1060,"publisherRelationship":1061,"citationCount":20,"citationInfo":20,"publishDate":1117,"publishYear":1118,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":1119,"openAccess":20,"references":20,"isForceReanalyzing":1120},"004a24f7-7491-495c-9f55-195964165259","2023-12-20T17:14:25.463+00:00","2025-01-21T09:35:40.348+00:00",[],"Phase-1-trial-of-Anvirzel-in-patients-with-refractory-solid-tumors",{"abstract":964,"title":966,"references":968,"doi":970},{"EN":965},"AnvirzelTM is an aqueous extract of the plant Nerium oleander which has been utilized to treat patients with advanced malignancies. The current study reports a phase 1 trial to determine the maximum tolerated dose (MTD) and safety of AnvirzelTM in patients with advanced, refractory solid tumors. Patients were randomized to receive this agent by intramuscular injection at doses of 0.1, 0.2, 0.4 ml\u002Fm2\u002Fday with subsequent patients receiving 0.8 or 1.2 ml\u002Fm2\u002Fday sequentially. Eighteen patients were enrolled and completed at least one treatment cycle of three weeks. Most patients developed mild injection site pain (78%). Other toxicities included fatigue, nausea, and dyspnea. Traditional dose limiting toxicity was not seen, but the MTD was defined by injection volume as 0.8 ml\u002Fm2\u002Fday. No objective anti-tumor responses were seen. Anvirzel™ can be safely administered at doses up to 1.2 ml\u002Fm2\u002Fday, with the amount administered intramuscularly limited by volume. The recommended phase II dose level is 0.8 ml\u002Fm2\u002Fday.",{"EN":967},"Phase 1 trial of Anvirzel™ in patients with refractory solid tumors",{"VOID":969},"Langford SD, Boor PJ (1996) Oleander toxicity: An examination of human and animal toxic exposures. Toxicology 109(1):1–13\nManna SK, Sah NK, Newman R, Cismerps A, Aggarwal BB (2000) Oleandrin suppresses activation of nuclear transcription of factor-B, activator protein-2 and c-Jun NH2-terminal kinase. Cancer Res 60:3838–3847\nAbe F, Yamaguchi T (1978) Digitoxigenin oleandroside and 5α-Adynerin in the leaves of Nerium odorum. Chem Pharm Bull 26:3023–3027\nAbe F, Yamaguchi T (1979) Oleasides-novel cardenolies with an unusual framework on Nerium. Chem Pharm Bull 27:1604–1610\nWang X, Plomley JB, Newman RA, Cisneros A (2000) LC(MS(MS analyses of an oleander extract for cancer treatment. Anal Chem 72(15):3547–3552\nSmith JA, Madden T, Vijjeswarapu M, Newman RA (2001) Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU 145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 62(4):469–472\nJortani SA, Helm RA, Valdes R (1996) Inhibition of Na,K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem 42:1654–1658\nPathak S, Multani AS, Narayan S, Kumar V, Newman RA (2000) Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 11(6):455–463\nMcConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA (2000) Cardiac glycosides stimulate Ca increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 60(14):3807–3812\nWHO (1979) Handbook for Reporting Results for Cancer Therapy. WHO, Geneva\nGupta A, Joshi P, Jortani SA, Valdes R Jr, Thorkelsson T, Verjee Z, Shemie S (1997) A case of nondigitalis cardiac glycoside toxicity. The Drug Monit 19(6):711–714",{"VOID":971},"10.1007\u002Fs10637-006-7772-x","PUBLICATION","2025-01-21T09:35:40.347+00:00","Auto Verify","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10637-006-7772-x",[977,993,1008,1021,1034,1047],{"id":978,"sortIndex":21,"researcher":20,"roles":979,"affiliations":981,"properties":990},"0a83ece3-292c-4652-80ed-0fe485c48f9e",[980],"AUTHOR",[982],{"id":983,"sortIndex":21,"affiliation":984,"properties":20},"0a9b78cb-b06a-4344-a42d-5d0a7b4897be",{"id":983,"createTime":20,"updateTime":20,"relativeEntities":985,"slug":20,"properties":986,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":989,"statistic":20},[],{"title":987},{"VI":988},"Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Case Comprehensive Cancer Center, Cleveland",[],{"title":991},{"VI":992},"Tarek Mekhail",{"id":994,"sortIndex":99,"researcher":20,"roles":995,"affiliations":996,"properties":1005},"34e5b854-f2c0-496c-b50a-f5b38ff23827",[980],[997],{"id":998,"sortIndex":21,"affiliation":999,"properties":20},"d79cd41a-1dc4-4eb4-ad79-2919ae648b95",{"id":998,"createTime":20,"updateTime":20,"relativeEntities":1000,"slug":20,"properties":1001,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1004,"statistic":20},[],{"title":1002},{"VI":1003},"Ireland Cancer Center, University Hospitals, Case Comprehensive Cancer Center, Ireland",[],{"title":1006},{"VI":1007},"Hanspreet Kaur",{"id":1009,"sortIndex":100,"researcher":20,"roles":1010,"affiliations":1011,"properties":1018},"2e68fd01-7af5-475a-bc0a-eacb8e2b1ef0",[980],[1012],{"id":983,"sortIndex":21,"affiliation":1013,"properties":20},{"id":983,"createTime":20,"updateTime":20,"relativeEntities":1014,"slug":20,"properties":1015,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1017,"statistic":20},[],{"title":1016},{"VI":988},[],{"title":1019},{"VI":1020},"Ram Ganapathi",{"id":1022,"sortIndex":101,"researcher":20,"roles":1023,"affiliations":1024,"properties":1031},"4b5ffea1-d5e5-4862-b7a7-f0cdf4b8d819",[980],[1025],{"id":983,"sortIndex":21,"affiliation":1026,"properties":20},{"id":983,"createTime":20,"updateTime":20,"relativeEntities":1027,"slug":20,"properties":1028,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1030,"statistic":20},[],{"title":1029},{"VI":988},[],{"title":1032},{"VI":1033},"G. Thomas Budd",{"id":1035,"sortIndex":142,"researcher":20,"roles":1036,"affiliations":1037,"properties":1044},"0ab6a2da-e06b-4f68-9d29-34bad2f0ef70",[980],[1038],{"id":983,"sortIndex":21,"affiliation":1039,"properties":20},{"id":983,"createTime":20,"updateTime":20,"relativeEntities":1040,"slug":20,"properties":1041,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1043,"statistic":20},[],{"title":1042},{"VI":988},[],{"title":1045},{"VI":1046},"Paul Elson",{"id":1048,"sortIndex":143,"researcher":20,"roles":1049,"affiliations":1050,"properties":1057},"22308cc2-4ff9-4bb6-a260-a1efe1b09f37",[980],[1051],{"id":983,"sortIndex":21,"affiliation":1052,"properties":20},{"id":983,"createTime":20,"updateTime":20,"relativeEntities":1053,"slug":20,"properties":1054,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1056,"statistic":20},[],{"title":1055},{"VI":988},[],{"title":1058},{"VI":1059},"Ronald M. Bukowski","ARTICLE",{"url":975,"publisher":1062,"properties":1112},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1063,"slug":10,"properties":1064,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1068,"manageAffiliations":1081,"indexDatabases":1092,"url":94,"thumbnailPath":20,"statistic":1107,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":1065,"title":1066,"eissn":1067},{"VOID":13},{"EN":15},{"VOID":17},[1069,1073,1077],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1070,"label":1071,"description":1072,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1074,"label":1075,"description":1076,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1078,"label":1079,"description":1080,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[1082,1087],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":1083,"slug":20,"properties":1084,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1086,"statistic":20},[],{"title":1085},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":1088,"slug":20,"properties":1089,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1091,"statistic":20},[],{"title":1090},{"EN":54},[],[1093,1100],{"id":58,"indexDatabase":1094,"url":71,"indexYears":20,"academicFieldIds":1099,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":1095,"label":1096,"description":1097,"key":67,"publicationTags":1098,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":1101,"url":87,"indexYears":88,"academicFieldIds":1106,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":1102,"label":1103,"description":1104,"key":84,"publicationTags":1105,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":1108,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":1109,"totalCitation":21,"totalCitationByYear":1110,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1111,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":1113,"volume":1115},{"VOID":1114},"423-427",{"VOID":1116},"24","2006-04-05",2006,[69,93],false,{"id":1122,"createTime":1123,"updateTime":1124,"relativeEntities":1125,"slug":1126,"properties":1127,"entityType":972,"verifyStatus":127,"verifyTime":1124,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1136,"fullTextUrl":20,"authors":1137,"publicationType":1060,"publisherRelationship":1192,"citationCount":20,"citationInfo":20,"publishDate":1248,"publishYear":1249,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":1250,"openAccess":20,"references":20,"isForceReanalyzing":1120},"0055103f-5170-4cda-8467-e4bb2432417a","2023-12-28T04:52:20.475+00:00","2024-12-07T16:54:10.603+00:00",[],"Development-of-Multidrug-Resistance-Convertors-Sense-or-Nonsense-",{"abstract":1128,"title":1130,"references":1132,"doi":1134},{"EN":1129},"This review describes the clinical relevance of the two drugtransporters P-glycoprotein (Pgp) and multidrugresistance-associated protein (MRP) and the in vitrophenomenon which is referred to as multidrug resistance (MDR).The attempts to try to block these resistance mechanisms aresummarized with specific attention for the intentionallydesigned ``second generation'' MDR-convertors. Potentialexplanations of the limited clinical success rate are given andrecommendations for the design of future studies provided.",{"EN":1131},"Development of Multidrug-Resistance Convertors: Sense or Nonsense?",{"VOID":1133},"Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152–162, 1976\nSharom, FJ: The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160: 161–175, 1997\nGottesman, MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427, 1993\nTwentyman PR: Transport proteins in drug resistance: biology and approaches to circumvention. J Intern Med 242: 133–137, 1997\nGermann UA: P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927–944, 1996\nHiggins CF, Gottesman MM: Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18–21, 1992\nZhu BT: A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol Carcinog 25: 1–13, 1999\nCordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277–1287, 1990\nChaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85–94, 1991\nDrach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber J, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80: 2729–2734, 1992\nSchinkel AH, Smit JJ, van Teffingen 0, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491–502, 1994\nSchinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JMJM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028–4033, 1997\nSchinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJM, Borst P: Multidrug resistance and the role of Pglycoprotein knockout mice. Eur J Cancer 31 A: 1295–1298, 1995\nLankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxic Appl Pharmacol 143: 357–365, 1997\nCole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science 258: 1650–1654, 1992\nCole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902–5910, 1994\nVanhoefer U, Cao S, Harstrick A, Seeber S, Rusturn YM: Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 8: 1221–1228, 1997\nJedlitschky G, Leier I, Buchholz U, Center M, Keppler D: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833–4836, 1994\nJedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucoronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988–994, 1996\nBarnouin K, Leier I, Jedlitschky G, Pourtier-Manzanedo A, König J, Lehmann WD, Keppler D: Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer 77: 201–209, 1998\nPriebe W, Krawczyk M, Tien Kuo M, Yamane Y, Savaraj N, Ishikawa T: Doxorubicin-and daunorubicin-glutathione conjugates, but not unconjugated drugs, compelitively inhibit leukotrione C4 transport mediated by MRP\u002FGS-X pump. Biochem Biophys Res Commun 247: 859–863, 1998\nZaman GJ, Lankelma J, van Tellingen 0, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst: Role of glutathione in the export of compounds from protein. Prot Natl Acid Sci USA 92: 7690–7694, 1995\nLoe DW, Deeley RG, Cole SPC: Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP). Evidence for cotransport with reduced glutathione. Cancer Res 58: 5130–5136, 1998\nIshikawa T, Bao JJ, Yamana Y, Akimaru K, Frindrich K, Wright CD, Kuo MT: Coordinated induction of MRP\u002FGSX pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981–14988, 1996\nRoelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, Jansen PLM, Muller M: Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112: 511–521, 1997\nEvers R, Zaman GJR, van Deemster L, Jansen H, Calafat J, Oomen LCJM, Oude Elferink RPJ, Borst P, Schinkel AH: Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97: 1211–1218, 1996\nWijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper FJ, Borst P: Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 188 (5): 397–808, 1998\nNooter K, Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768–780, 1996\nLoe DW, Deeley RG, Cole SPC: Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A: 945–957, 1996\nDeeley RG, Cole SPC: Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8: 193–204, 1997\nWijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3: 1275–1279, 1997\nRappa G, Lorico A, Flavelli RA, Sartorelli AC: Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res 57: 5232–5237, 1997\nNooter K, Herweijer H: Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663–669, 1991\nHotta T. Tanimura H, Tsunoda T, lwahashi M, Tani M, Noguchi K, Mizobata S, Arii K, Terasawa H, Nakamori M, Yamaue H: P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells. Hepatogastroenterology 46: 316–321, 1999\nFilipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231–1237, 1996\nArao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto H: Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355–1359, 1994\nKavallaris M, Leary JA, Barrett JA, Friedlander ML: MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 102: 7–16, 1996\nChan HS, Haddad G, Thomer PS, DeBoer G, Lin YR Ondrusek N, Yeger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608–1614, 1991\nAbe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SPC, Koike K, Kuwano M, Hori S: Expression of multidrug resistance protein gene in patients with gborna after chemotherapy. J Neuro-Oncol 40: 11–18, 1998\nStein U, Walther W, Wunderlich V: Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 10: 1541–1545, 1994\nOda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowske A, Roessner A: Expression of multidrugresistance protein gene in human soft-tissue sarcomas. J Cancer Res Clin Oncol 122: 161–165, 1996\nBroxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Wahrer DC, Ossenkoppele GJ, Schuurhuis GJ: Theoretical and practical considerations for the measurement of P217 glycoprotein function in acute myeloid leukemia. Leukemia 11: 1110–1118, 1997\nWebb M, Brun M, McNiven M, Le Couteur D, Craft P: MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 102: 710–717, 1998\nHokmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486–1491, 1992\nWillman CL: The prognostic significance of the expression and function of multidrug-resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34: 25–33, 1997\nLeith C, Kopecky K, Godwin J, McConnell T, Slovak ML, Chen l-M, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukernia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323–3329, 1997\nWeinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS: Relationship of the expression of the multidrug resistance gene product (Pglycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720–2726, 1991\nCampos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphocytic leukemia cells at diagnosis. Blood 79: 473–476, 1992\nGoasguen JE, Dossot J-M, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81: 2394–2398, 1993\nZochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R: P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8: 974–977, 1994\nGuerci A, Merlin JL, Missourn N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and p-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147–2153, 1995\nBaldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380–1385, 1995\nChin K-V, Kazumitsu U, Pastan 1, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459–462, 1992\nThorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236: 1120–1122, 1987\nSchinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E: N-glycosylation and deletion mutants of the human mdr1 Pglycoprotein. J Biol Chem 268: 7474–7481, 1993\nNooter K, Westerman AM, Flens MJ, Zaman, GJR, Scheper, RJ, Van Wingerden KE, Burger, H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT, Stoter G: Expression of the multidrug resistanceassociated (MRP) gene in human cancers. Clin Cancer Res 1: 1301–1310, 1995\nFilipits M, Suchomel RW, Dekan G, Stigibauer W, Haider K, Depisch D, Pirker R: Expression of the multidrug resistanceassociated protein (MRP) gene in colorectal carcinomas. Br J Cancer 75: 208–212, 1997\nNooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486–493, 1997\nNooter K, Brutel de la Riviere G, Klijn J, Stoter G, Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet 349: 1885–1886, 1997\nNooter K, Kok, T, Bosman FT, van Wingerden KE, Stoter G: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur J Cancer 34: 81–86, 1998\nTakebayashi Y, Akiyama S, Natsugoe S, Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T, Aikou T: The expression of muffidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82: 661–666, 1998\nOta E, Abe Y, Oshika Y, Ozeki Y, lwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N, Nakamura M: Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72: 550–554, 1995\nNarasaki F, Matsuo I, Ikuno N, Fukuda M, Soda H, Oka M: Multidrug resistanceassociated protein (MRP) gene expression in human lung cancer. Anticancer Res 16: 2079–2082, 1996\nNooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, Oostrum RG, Boersma AWM, van der Gaast A, Stoter G. Expression of the multidrug resistanceassociated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 7: 75–81, 1996\nCampling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH: Expression of the MRP and MDR1 multidrug resistance gene in small cell lung cancer. Clin Cancer Res 3: 115–122, 1997\nBerger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M: Possible role of the multidrug resistanceassociated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 71: 108–115, 1997\nBurger H, Nooter K, Zaman G.I. Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8: 990–997, 1994\nBurger H, Nooter K, Sonneveld P, van Wingerden KE, Zaman GJ, Stoter G: High expression of the multidrug resistanceassociated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 88: 348–356, 1994\nNorris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M: Expression of the gene for multidrug-resistanceassociated protein and outcome in patients with neuroblastoma. N Engl J Med 334: 231–238, 1996\nNooter K, Oostrum R, Jonker R, van Dekken H, Stoikdijk W, van den Engh G: Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemother Pharmacol 23: 296–300, 1989\nTwentyman PR: MDR1 (P-glycoprotein) gene expression-Implications for resistance modifiers trials. J Natl Cancer Inst 84: 1458–1460, 1992\nFine RL: Multidrug resistance. Cancer Chemother Biol Response Modif 10: 73–84, 1989\nTsuruo T, lida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukernia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972, 1981\nFord JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199, 1990\nBradshaw DM, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16 (11): 3674–3690, 1998\nAdvani R, Saba H, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukernia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93: 787–795, 1999\nPlanting AST, van der Gaast A, Sparreboom A, van der Burg MEL, de Boer M, Wissel PS, Jewell RC, Paul EM, Verweij J: Phase I and pharmacokinetic (PK) study targeting a 100 ng\u002FmL plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (dox) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 199a, 1998 (abstract)\nFerry D, Moore M, Bartlett NL, Fyfe D, Oza A, Fracasso PM, Kersey K, Wissel PS, Jewell RC, Paul EM. Phase I and pharmacokinetic study targeting a 500 ng\u002Fml plasma concentration of the potent multidrug resistance modulator GF120918 with doxorubicin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 922, 1998 (abstract)\nRowinsky EK, Smith L, Wang Y-M, Chaturvedi P, Vilialona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson Jr J, Harding MW, Von Hoff DD: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16: 2964–2976, 1998\nPeck RA, Marshall J, Ziessman H, Hewett J, Schmalbach T, Chatuvedi P, Hawkins M: A phase I trial of doxorubicin and VX-710. Proc Am Assoc Cancer Res 37: 165, 1996 (abstract)\nvan Zuylen L, Sparreboom A, van der Gaast A, van der Berg MEL, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J: The orally administered P-glycoprotein inhibitor R101933 does not alter the pharmacokinetics of docetaxel results of a phase I study. Clin Cancer Res 6: 1365–1371, 2000\nAwada A, Bleiberg H, Gil T, Di Leo A, Geurs F, de Valeriola D, McCabe S, Palmer PA, Woestenborghs R, Bol CJJG, Piccart MJ: Oral R101933, an inhibitor ofMDR1 P-glycoprotein does not significantly alter the pharmacokinetics and pharmacodynamics of paclitaxel. Proc Am Ass Cancer Res 40: 4373, 1999 (abstract)\nNaito M, Tsuruo T: New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol 40: S20-S24, 1997\nNaito S, Koike K, Ono M, Machida T, Tasaka S, Kiue A, Koga H, Kumazawa J: Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1-and MRPmediated multidrug resistance. Oncol Res 10: 123–132, 1998\nDantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt W, Baughman TM, Bumol TF, Starling JJ: Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyidibenzosuberane modulator, LY335979. Cancer Res 56: 4171–4179, 1996\nRoe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595–600, 1999\nMistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Chariton P, Templeton D, Bevan PB: In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer 79: 1672–1678, 1999\nBeck JF, Buchholz F, Ulrich W-R, Boer R, Sanders KH, Niethammer D, Gekeler V: Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309–068, a newly designed pyridine derivative. Cancer Lett 129: 157–163, 1998\nChen H, Bamberger U, Heckel A, Guo X, Cheng Y: BIBW-22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 53: 1974–1977, 1993\nList AF, Chakos H, Glinsmann-Gibson B, Bamberger U: Reversal of classical and non-P-glycoprotein (PGP)-mediated multidrug resistance (MDR) by BIBW-22. Blood 86: 516a, 1995 (abstract)\nGekeler V, Ise W, Sanders KH, Urich W, Beck J: The leukotreine LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208: 345–352, 1995\nVanhoefer U, Cao S, Minderman H, Tóth K, Scheper RJ, Slovak ML, Rusturn YM: PAK-104P, a pyridine analogue reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2: 369–377, 1996\nBeketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI: Decreased mutation rate for doxorubicin resistance and suppression of mdr1 gene activation by PSC 833. J Natl Cancer Inst 87: 1593–1602, 1995\nBeck WT, Grogan TM, Wiliman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R: Methods to detect P-glycoproteinassociated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010–3020, 1996\nDalton WS, Grogan T, Salmon SE: Drug resistance in multiple myeloma. Cancer Res Ther Control 6: 189–190, 1998\nZaman GJR, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P: The human multidrug resistanceassociated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822–8826, 1994\nBreuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD: Expression of multidrug resistanceassociated protein in NIH\u002F3T3 cells confers multidrug resistance associated with increased efflux and altered intracellular drug distribution. Cancer Res 55: 5342–5347, 1995\nVersantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J, Broxterman HJ: Genistein modu219 lates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68: 939–946\nVersantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM: Competitive inhibiton by genistein and ATPdependence of daunorubicin transport in intact MRP overexpressing human small-cell lung cancer cells. Biochem Pharmacol 48: 1129–1136, 1994\nVersantvoort CHM, Broxterman W, Bagrij T, Scheper RJ, Twentyman PR: Regulation of glutathione of drug transport in multidrug resitant human lung tumour cell lines overexpressing MRP. Br J Cancer 72: 82–89, 1995\nZaman GJR, Lankelma J, van Tellingen O, Beijen J, Dekker H, Paulusma C, Oude Sferink RPJ, Baas F, Borst P: Role of glutathione in the export of compounds from cells by the multidrug-resitance-associated protein. Proc Natl Acad Sci USA 92: 7690–7694, 1995\nFord JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res 51: 67–72, 1991\nLai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE: Contribution of glutathione and glutathione-dependent enzymes in the reversal of Adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49: 688–695, 1991\nMa L, Krishnarnachary N, Center MS: Phosporylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338–3343,1995\nBertram J, Paifner K, Killian M, Brysch W, Schlingensiepen K-H, Hiddemann W, Kneba M: Reversal of multiple drug resistance in vitro by phosphorothioate olignucleotides and ribozymes. Anticancer Drugs 6: 124–134, 1995\nStewart AJ, Canitrot Y, Baracchini E, Dean NK Deeley RG, Cole SPC: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate olignucleotides. Biochem Pharmacol 51: 461–469, 1996\nRubin SC, Finstad CL, Hoskins WJ, Saigo PF, Provencher DM, Federici MG, Hakes TB, Markman M, Reichman BS, Lloyd KO, Lewis JL: Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 163: 69–73, 1990\nLehnert M, de Giuli R, Kunke K, Emerson S, Dalton WS, Salmon SE: Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur J Cancer 32A: 862–867, 1996\nSmith AJ, Mayer U, Schinkel AH, Borst P: Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 90: 1161–1166, 1998\nFuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58: 3248–3253, 1998\nTunggal X, Ballinger JR, Tannock IF: Influence of cell concentration in limiting the therapeutic benefit of Pglycoprotein reversal agent. Int J Cancer 81: 741–747, 1999\nRelling MV: Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18: 350–356, 1996\nFields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L: PSC833: initial results in refractory ovarian cancer patients. Curr Opin Oncol 10: S21, 1998\nSonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, and Löwenberg: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. Leukemia 10: 1741–1750, 1996\nBoote DJ, Dennis IF, Twentyrnan PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610–618, 1996\nKornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukernia. J Clin Oncol 15: 1796–1802, 1997\nGiaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJF, Eeltink C, Vermorken JB, Pinedo HM: A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3: 2005–2015, 1997\nList AF, Spier C, Greer J, WoIff S, Hutter J, Dorr R, Salmon SE, Futcher B, Baier M, Dalton W: Phase I\u002FII trial of cyclosporin as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11: 1652–1660, 1993\nBartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI: Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 12: 835–842, 1994\nYahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI: A phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 10: 1624–1634, 1992\nErlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, De Angelis C, Bunting P: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837–4842, 1993\nPinedo HM, Giaccone G: P-glycoprotein-a marker of cancer-cell behavior. N Engl J Med 333: 1417–1419, 1995 (editorial)\nKool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537–3547, 1997\nDalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424, 1989\nDalton WS, Crowley JJ, Salmon S, Grogan TM, Laufman LR, Weiss G, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patient with refractory myeloma: A Southwest Oncology Group Study. Cancer 75: 815–820, 1995\nSonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–259, 1992\nTallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM: Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group pilot Study. Cancer 85: 358–367, 1999\nSolary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn J-Y, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Ifrah N, Lamy Y, Audhuy B, Colombat P, Harousseau J-L: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88: 1198–1205, 1996\nMiller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphorna and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17–24, 1991\nWilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995–2004, 1995\nMiller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE: A phase I\u002FII trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs 9: 135–140, 1998\nMilroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 68: 813–818, 1993\nRoss HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM: Phase I\u002FII trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer 18: 189–198, 1997\nTolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MR, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaughnessy JA: Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14: 1173–1184, 1996\nWishart G, Bisset D, Paul J, Harnett JA, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB: Quinidine as a resitance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771–1777, 1994\nWarner E, Heffley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R: Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4: 1451–1457, 1998\nVerweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting ASTh, Seynaeve C, Stoter G, Nooter K: A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64: 361–364, 1991\nRodenburg CJ, Nooter K, Herweijer H, Seynaeve, Oosterom R, Stoter G, Verweij J: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2: 305–306, 1991\nMayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430–2436,1997\nSparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454–1457, 1999\nHyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acrid inecarboxam ide derivative. Cancer Res 53: 4595–4602, 1993\nSparreboom A, Planting AST, Jewell RC, de Bruijn P, Loos WJ, Paul EM, Wissel PS, Nooter K, Stoter G, Verweij J: Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti Cancer Drugs, in press\nPiwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multi-drug resistant P-glycoprotein with an organtechnetium complex. Cancer Res 53: 977–984, 1993\nDel Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfil C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M: Fractional retention of Technetium-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38: 1348–1351, 1997\nChen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, Bates SE: Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m Sestamibi. Clin Cancer Res 3: 545–552, 1997\nHendriks NH, Franssen EJF, van der Graaf WTA, Meijer C, Piers DA, Vaalburg W, de Vries EGE: 99m-Tc-sestamibi is a substrate for P-glycoprotein and the multidrug resistanceassociated protein. Br J Cancer 77: 353–358, 1998\nWhitherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS: Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7–12, 1996\nRobey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T, Bates S: Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoproteinmediated drug efflux by PSC 833. Blood 93: 306–314\nRuetz S, Brault M, Dalton W, Gros P: Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. Biochemistry 36: 8180–8188, 1997\nRingel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxel. J Natl Cancer Inst 83: 288–291, 1991\nSchinkel AH, Wagenaar E, Mol CA, van Deemter L: Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517–2524, 1996",{"VOID":1135},"10.1023\u002FA:1006487003814","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1023\u002FA:1006487003814",[1138,1153,1166,1179],{"id":1139,"sortIndex":21,"researcher":20,"roles":1140,"affiliations":1141,"properties":1150},"5bb32bd9-addb-4c16-9576-19d3471bba59",[980],[1142],{"id":1143,"sortIndex":21,"affiliation":1144,"properties":20},"9e918a1d-6896-49f3-85cc-5224f87c035e",{"id":1143,"createTime":20,"updateTime":20,"relativeEntities":1145,"slug":20,"properties":1146,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1149,"statistic":20},[],{"title":1147},{"VI":1148},"Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, the Netherlands",[],{"title":1151},{"VI":1152},"Lia van Zuylen",{"id":1154,"sortIndex":99,"researcher":20,"roles":1155,"affiliations":1156,"properties":1163},"0a38cc2c-ed5c-492a-ae9a-36c073a84845",[980],[1157],{"id":1143,"sortIndex":21,"affiliation":1158,"properties":20},{"id":1143,"createTime":20,"updateTime":20,"relativeEntities":1159,"slug":20,"properties":1160,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1162,"statistic":20},[],{"title":1161},{"VI":1148},[],{"title":1164},{"VI":1165},"Kees Nooter",{"id":1167,"sortIndex":100,"researcher":20,"roles":1168,"affiliations":1169,"properties":1176},"0a4e63d3-5744-4355-a6fc-b3351ebbc359",[980],[1170],{"id":1143,"sortIndex":21,"affiliation":1171,"properties":20},{"id":1143,"createTime":20,"updateTime":20,"relativeEntities":1172,"slug":20,"properties":1173,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1175,"statistic":20},[],{"title":1174},{"VI":1148},[],{"title":1177},{"VI":1178},"Alex Sparreboom",{"id":1180,"sortIndex":101,"researcher":20,"roles":1181,"affiliations":1182,"properties":1189},"0fbac79e-4251-4c6c-b5b0-291e4d4f2a0e",[980],[1183],{"id":1143,"sortIndex":21,"affiliation":1184,"properties":20},{"id":1143,"createTime":20,"updateTime":20,"relativeEntities":1185,"slug":20,"properties":1186,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1188,"statistic":20},[],{"title":1187},{"VI":1148},[],{"title":1190},{"VI":1191},"Jaap Verweij",{"url":1136,"publisher":1193,"properties":1243},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1194,"slug":10,"properties":1195,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1199,"manageAffiliations":1212,"indexDatabases":1223,"url":94,"thumbnailPath":20,"statistic":1238,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":1196,"title":1197,"eissn":1198},{"VOID":13},{"EN":15},{"VOID":17},[1200,1204,1208],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1201,"label":1202,"description":1203,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1205,"label":1206,"description":1207,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1209,"label":1210,"description":1211,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[1213,1218],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":1214,"slug":20,"properties":1215,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1217,"statistic":20},[],{"title":1216},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":1219,"slug":20,"properties":1220,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1222,"statistic":20},[],{"title":1221},{"EN":54},[],[1224,1231],{"id":58,"indexDatabase":1225,"url":71,"indexYears":20,"academicFieldIds":1230,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":1226,"label":1227,"description":1228,"key":67,"publicationTags":1229,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":1232,"url":87,"indexYears":88,"academicFieldIds":1237,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":1233,"label":1234,"description":1235,"key":84,"publicationTags":1236,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":1239,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":1240,"totalCitation":21,"totalCitationByYear":1241,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1242,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":1244,"volume":1246},{"VOID":1245},"205-220",{"VOID":1247},"18","2000-08-01",2000,[69,93],{"id":1252,"createTime":1253,"updateTime":1254,"relativeEntities":1255,"slug":1256,"properties":1257,"entityType":972,"verifyStatus":127,"verifyTime":1254,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1268,"fullTextUrl":20,"authors":1269,"publicationType":1060,"publisherRelationship":1446,"citationCount":20,"citationInfo":20,"publishDate":1497,"publishYear":1498,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":1499,"openAccess":20,"references":20,"isForceReanalyzing":1120},"00c7a7e6-4196-4eb3-8b0a-2c7b3b939ddf","2024-04-06T14:37:56.660+00:00","2024-12-18T13:27:05.727+00:00",[],"Prediction-of-response-to-everolimus-in-neuroendocrine-tumors-evaluation-of-clinical-biological-and-histological-factors",{"abstract":1258,"title":1260,"keywords":1262,"references":1264,"doi":1266},{"EN":1259},"\n                        Objectives Several targeted therapies are available for metastatic neuroendocrine tumours (NETs) but no predictive factor of response to these treatments has been identified yet. Our aim was to identify and evaluate clinical, biological, histological and functional markers of response to everolimus. Methods We retrospectively reviewed 53 patients with NETs treated with everolimus (68 % in clinical trials). Clinical, biological and histological data were analyzed. The functional marker p-p70S6K, a main effector of the mTOR pathway, was studied by immunohistochemistry in 43 cases. Prognostic factors of progression-free survival (PFS) were studied by Kaplan Meier analysis. Results All patients had metastatic and progressive disease before everolimus treatment. Objective response was 9 % and median PFS was 8.1 (4.7–11.5) months. Hypercholesterolemia (HR = 0.13, p \u003C 0.0001) was associated with longer PFS, whereas presence of bone metastases (HR = 3.1, p \u003C 0.001) and overexpression of p-p70S6K by tumor cells (HR = 2.5, p = 0.01) were associated with shorter PFS under everolimus at multivariate analysis. Conclusion Clinical markers are not useful to predict response to everolimus. However, occurrence of hypercholesterolemia under treatment may be an early marker of response. Prospective studies are required to confirm these results and to assess whether p-p70S6K immunostaining is a prognostic or predictive marker of no-response to everolimus.",{"EN":1261},"Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors",{"EN":1263},"",{"VOID":1265},"Yao JC, Hassan M, Phan A, et al. (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol Off J Am Soc Clin Oncol 26:3063–3072\nPavel ME, Hainsworth JD, Baudin E, et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012\nYao JC, Fazio N, Singh S et al. (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–77. doi: 10.1016\u002FS0140-6736(15)00817-X.\nYao JC, Shah MH, Ito T, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523\nGalanis E, Buckner JC, Maurer MJ, et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol Off J Am Soc Clin Oncol 23:5294–5304\nLee CK, Marschner IC, Simes RJ, et al. (2012) Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res: An Official Journal of the American Association for Cancer Research 18:3188–3196\nRavaud A, Urva SR, Grosch K, et al. (2014) Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer 50:486–495\nNeshat MS, Mellinghoff IK, Tran C, et al. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\u002FmTOR. Proc Natl Acad Sci U S A 98:10314–10319\nJanku F, Wheler JJ, Westin SN, et al. (2012) PI3K\u002FAKT\u002FmTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 30:777–782\nIyer G, Hanrahan AJ, Milowsky MI, et al. (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221\nBollard J, Couderc C, Blanc M, et al. (2013) Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology 97:331–340\nCho D, Signoretti S, Dabora S, et al. (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379–385\nDuran I, Kortmansky J, Singh D, et al. (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148–1154\nYoon DH, Ryu MH, Park YS, et al. (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106:1039–1044\nLombard-Bohas C, Cariou B, Verges B, et al. (2014) Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals. Bull Cancer 101:175–183\nVerges B, Walter T, Cariou B (2014) ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170:R43–R55\nBilimoria KY, Talamonti MS, Tomlinson JS, et al. (2008) Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 247:490–500\nKhan MS, Kirkwood A, Tsigani T, et al. (2013) Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol 31:365–372\nCapurso G, Archibugi L, Delle Fave G (2015) Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 22(8):594–601. doi:10.1002\u002Fjhbp.210.\nMissiaglia E, Dalai I, Barbi S, et al. (2009) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol Off J Am Soc Clin Oncol 28:245–255\nQian ZR, Ter-Minassian M, Chan JA, et al. (2013) Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol 31:3418–3425\nSharpe LJ, Brown AJ (2008) Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun 373:670–674\nCustodio AJ-FP, Alonso-Orduña V, López López C, Alonso T, Guillermo C, Carmona-Bayonas A, Álvarez-Escolá CSM, Capdevila J, Grande E, Barriuso J, Feliu J, Aller J (2015) Everolimus (EVE)-induced hyperglycemia (HG) in patients (pts) with advanced G1-G2 neuroendocrine tumors (NETs): clinical relevance and predictive value. ENETS - The European Neuroendocrine Tumor Society. Barcelona, In\nRugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R (2016) Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27(3):519–525. doi:10.1093\u002Fannonc\u002Fmdv595.\nTempleton AJ, Dutoit V, Cathomas R, et al. (2013) Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\u002F08). Eur Urol 64:150–158",{"VOID":1267},"10.1007\u002Fs10637-016-0363-6","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10637-016-0363-6",[1270,1301,1314,1327,1340,1353,1380,1395,1408,1421],{"id":1271,"sortIndex":21,"researcher":20,"roles":1272,"affiliations":1273,"properties":1298},"a6d4318d-79e0-4f03-a989-739721133d70",[980],[1274,1282,1290],{"id":1275,"sortIndex":21,"affiliation":1276,"properties":20},"3dd6e302-cd9d-4305-87e5-72ed51e888ad",{"id":1275,"createTime":20,"updateTime":20,"relativeEntities":1277,"slug":20,"properties":1278,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1281,"statistic":20},[],{"title":1279},{"VI":1280},"Service d’hépatogastroentérologie et d’oncologie digestive, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon cedex 03, France",[],{"id":1283,"sortIndex":21,"affiliation":1284,"properties":20},"6d88159c-8f1e-45d6-abe6-d2e6e0ea10d5",{"id":1283,"createTime":20,"updateTime":20,"relativeEntities":1285,"slug":20,"properties":1286,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1289,"statistic":20},[],{"title":1287},{"VI":1288},"Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne Cedex, France",[],{"id":1291,"sortIndex":21,"affiliation":1292,"properties":20},"955973a5-45c3-4f6c-8b1b-5e59e1ec7875",{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1293,"slug":20,"properties":1294,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1297,"statistic":20},[],{"title":1295},{"VI":1296},"INSERM, UMR 1052, Lyon Cancer Research Center, Faculté Laennec, Lyon Cedex 08, France",[],{"title":1299},{"VI":1300},"Noura Benslama",{"id":1302,"sortIndex":99,"researcher":20,"roles":1303,"affiliations":1304,"properties":1311},"0ef8c1f0-d2b9-4dfe-ac87-8bc2b3db28d2",[980],[1305],{"id":1291,"sortIndex":21,"affiliation":1306,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1307,"slug":20,"properties":1308,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1310,"statistic":20},[],{"title":1309},{"VI":1296},[],{"title":1312},{"VI":1313},"Julien Bollard",{"id":1315,"sortIndex":100,"researcher":20,"roles":1316,"affiliations":1317,"properties":1324},"8781014f-8d6f-43e6-b014-0b66467af867",[980],[1318],{"id":1291,"sortIndex":21,"affiliation":1319,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1320,"slug":20,"properties":1321,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1323,"statistic":20},[],{"title":1322},{"VI":1296},[],{"title":1325},{"VI":1326},"Cécile Vercherat",{"id":1328,"sortIndex":101,"researcher":20,"roles":1329,"affiliations":1330,"properties":1337},"c939b2b7-c6a2-4ea8-8d5a-7c4cfd64b8c3",[980],[1331],{"id":1291,"sortIndex":21,"affiliation":1332,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1333,"slug":20,"properties":1334,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1336,"statistic":20},[],{"title":1335},{"VI":1296},[],{"title":1338},{"VI":1339},"Patrick Massoma",{"id":1341,"sortIndex":142,"researcher":20,"roles":1342,"affiliations":1343,"properties":1350},"19b5a283-c15c-4b4f-aacf-b72d3d03de4e",[980],[1344],{"id":1291,"sortIndex":21,"affiliation":1345,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1346,"slug":20,"properties":1347,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1349,"statistic":20},[],{"title":1348},{"VI":1296},[],{"title":1351},{"VI":1352},"Colette Roche",{"id":1354,"sortIndex":143,"researcher":20,"roles":1355,"affiliations":1356,"properties":1377},"50d7c91c-ecb9-4bf1-8091-7d64b81a743b",[980],[1357,1365,1371],{"id":1358,"sortIndex":21,"affiliation":1359,"properties":20},"47420bb6-2d13-4d8e-9159-dc7c10cf7aa7",{"id":1358,"createTime":20,"updateTime":20,"relativeEntities":1360,"slug":20,"properties":1361,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1364,"statistic":20},[],{"title":1362},{"VI":1363},"Service Central d’Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon Cedex 03, France",[],{"id":1283,"sortIndex":21,"affiliation":1366,"properties":20},{"id":1283,"createTime":20,"updateTime":20,"relativeEntities":1367,"slug":20,"properties":1368,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1370,"statistic":20},[],{"title":1369},{"VI":1288},[],{"id":1291,"sortIndex":21,"affiliation":1372,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1373,"slug":20,"properties":1374,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1376,"statistic":20},[],{"title":1375},{"VI":1296},[],{"title":1378},{"VI":1379},"Valérie Hervieu",{"id":1381,"sortIndex":145,"researcher":20,"roles":1382,"affiliations":1383,"properties":1392},"0fb153a8-b0c3-439a-9ef3-389ffca376bf",[980],[1384],{"id":1385,"sortIndex":21,"affiliation":1386,"properties":20},"ed10ff04-b085-429a-b86c-c2c0e0b45479",{"id":1385,"createTime":20,"updateTime":20,"relativeEntities":1387,"slug":20,"properties":1388,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1391,"statistic":20},[],{"title":1389},{"VI":1390},"Medical Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite, France",[],{"title":1393},{"VI":1394},"Julien Peron",{"id":1396,"sortIndex":146,"researcher":20,"roles":1397,"affiliations":1398,"properties":1405},"edccaf4d-b429-412d-8bd3-0c8b9c14c775",[980],[1399],{"id":1275,"sortIndex":21,"affiliation":1400,"properties":20},{"id":1275,"createTime":20,"updateTime":20,"relativeEntities":1401,"slug":20,"properties":1402,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1404,"statistic":20},[],{"title":1403},{"VI":1280},[],{"title":1406},{"VI":1407},"Catherine Lombard-Bohas",{"id":1409,"sortIndex":451,"researcher":20,"roles":1410,"affiliations":1411,"properties":1418},"ebeac045-4200-4172-ab60-b6598b581baf",[980],[1412],{"id":1291,"sortIndex":21,"affiliation":1413,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1414,"slug":20,"properties":1415,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1417,"statistic":20},[],{"title":1416},{"VI":1296},[],{"title":1419},{"VI":1420},"Jean-Yves Scoazec",{"id":1422,"sortIndex":240,"researcher":20,"roles":1423,"affiliations":1424,"properties":1443},"b7ca20f4-e2f9-438a-a43c-bcaaae9d5541",[980],[1425,1431,1437],{"id":1275,"sortIndex":21,"affiliation":1426,"properties":20},{"id":1275,"createTime":20,"updateTime":20,"relativeEntities":1427,"slug":20,"properties":1428,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1430,"statistic":20},[],{"title":1429},{"VI":1280},[],{"id":1283,"sortIndex":21,"affiliation":1432,"properties":20},{"id":1283,"createTime":20,"updateTime":20,"relativeEntities":1433,"slug":20,"properties":1434,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1436,"statistic":20},[],{"title":1435},{"VI":1288},[],{"id":1291,"sortIndex":21,"affiliation":1438,"properties":20},{"id":1291,"createTime":20,"updateTime":20,"relativeEntities":1439,"slug":20,"properties":1440,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1442,"statistic":20},[],{"title":1441},{"VI":1296},[],{"title":1444},{"VI":1445},"Thomas Walter",{"url":20,"publisher":1447,"properties":20},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1448,"slug":10,"properties":1449,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1453,"manageAffiliations":1466,"indexDatabases":1477,"url":94,"thumbnailPath":20,"statistic":1492,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":1450,"title":1451,"eissn":1452},{"VOID":13},{"EN":15},{"VOID":17},[1454,1458,1462],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1455,"label":1456,"description":1457,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1459,"label":1460,"description":1461,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1463,"label":1464,"description":1465,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[1467,1472],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":1468,"slug":20,"properties":1469,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1471,"statistic":20},[],{"title":1470},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":1473,"slug":20,"properties":1474,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1476,"statistic":20},[],{"title":1475},{"EN":54},[],[1478,1485],{"id":58,"indexDatabase":1479,"url":71,"indexYears":20,"academicFieldIds":1484,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":1480,"label":1481,"description":1482,"key":67,"publicationTags":1483,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":1486,"url":87,"indexYears":88,"academicFieldIds":1491,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":1487,"label":1488,"description":1489,"key":84,"publicationTags":1490,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":1493,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":1494,"totalCitation":21,"totalCitationByYear":1495,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1496,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},"2016-05-26",2016,[69,93],{"id":1501,"createTime":1502,"updateTime":1503,"relativeEntities":1504,"slug":1505,"properties":1506,"entityType":972,"verifyStatus":127,"verifyTime":1503,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1513,"fullTextUrl":20,"authors":1514,"publicationType":1060,"publisherRelationship":1608,"citationCount":20,"citationInfo":20,"publishDate":1664,"publishYear":1665,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":1666,"openAccess":20,"references":20,"isForceReanalyzing":1120},"013b31e4-22a0-4aa0-8763-6f13e44b0ced","2024-02-09T21:48:13.707+00:00","2024-12-12T17:57:38.478+00:00",[],"A-Southwest-Oncology-Group-phase-II-evaluation-of-fluderabine-monophosphate-in-sarcoma",{"title":1507,"references":1509,"doi":1511},{"EN":1508},"A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma",{"VOID":1510},"Morton DL, Antman KH, Tepper J: Soft Tissue Sarcoma. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine, 3rd edition. Lea & Febiger, Philadelphia, 1993, pp 1858–1887\nGrever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley R, Von Hoff DD, Balcerzak SP: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457–459, 1988\nLeiby JM, Kraut EH, Metz EN, Malspeis L, Grever MR: Phase II trial of 9-B-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deocytidine kinase activity. Cancer Res 47(10):2719–2722, 1987\nGrever M, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S, Malspeis L: A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 17(5):39–48, 1990\nVon Hoff D: Phase I clinical trials with fludarabine phosphate. Semin Oncol 17(5):33–38, 1990\nMerkel DE, Griffin NL, Kagan-Hallet K, Von Hoff DD: Central nervous system toxicity with fludarabine. Cancer Treat Rep 70(12):1449–1450, 1986",{"VOID":1512},"10.1007\u002FBF00873969","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF00873969",[1515,1533,1548,1563,1578,1593],{"id":1516,"sortIndex":21,"researcher":20,"roles":1517,"affiliations":1518,"properties":1530},"f1b8e84b-2473-47fa-b797-b25ce3ae1e64",[980],[1519],{"id":1520,"sortIndex":21,"affiliation":1521,"properties":1527},"d1129591-bd2d-4484-9f1c-8d4c690e5bfe",{"id":1520,"createTime":20,"updateTime":20,"relativeEntities":1522,"slug":20,"properties":1523,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1526,"statistic":20},[],{"title":1524},{"VI":1525},"National Cancer Institute, Bethesda, United States",[],{"title":1528},{"VI":1529},"National Cancer Institute, Bethesda, USA",{"title":1531},{"VI":1532},"Micheal R. Grever",{"id":1534,"sortIndex":99,"researcher":20,"roles":1535,"affiliations":1536,"properties":1545},"9a5e1555-9657-43e0-92c8-65306834105a",[980],[1537],{"id":1538,"sortIndex":21,"affiliation":1539,"properties":20},"1f4cf1bc-be40-4446-8051-135c22e49f03",{"id":1538,"createTime":20,"updateTime":20,"relativeEntities":1540,"slug":20,"properties":1541,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1544,"statistic":20},[],{"title":1542},{"VI":1543},"Southwest Oncology Group Statistical Center, Seattle, USA",[],{"title":1546},{"VI":1547},"Jacqueline Benedetti",{"id":1549,"sortIndex":100,"researcher":20,"roles":1550,"affiliations":1551,"properties":1560},"0eb77daf-4844-4ea6-81ed-0bc543240d3c",[980],[1552],{"id":1553,"sortIndex":21,"affiliation":1554,"properties":20},"851a7347-2be9-4fa9-a35f-4b423d3f66d5",{"id":1553,"createTime":20,"updateTime":20,"relativeEntities":1555,"slug":20,"properties":1556,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1559,"statistic":20},[],{"title":1557},{"VI":1558},"Ohio State University Health Center, Columbus, USA",[],{"title":1561},{"VI":1562},"Stanley P. Balcerzak",{"id":1564,"sortIndex":101,"researcher":20,"roles":1565,"affiliations":1566,"properties":1575},"81d142a6-340f-4c00-b04f-834911816a73",[980],[1567],{"id":1568,"sortIndex":21,"affiliation":1569,"properties":20},"17fbfd6b-fe5d-49f7-9a2b-39791b8098a7",{"id":1568,"createTime":20,"updateTime":20,"relativeEntities":1570,"slug":20,"properties":1571,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1574,"statistic":20},[],{"title":1572},{"VI":1573},"University of Kansas Medical Center, Kansas City, USA.",[],{"title":1576},{"VI":1577},"Sarah A. Taylor",{"id":1579,"sortIndex":142,"researcher":20,"roles":1580,"affiliations":1581,"properties":1590},"46e91b04-9855-4f8a-86e0-54f89953c28c",[980],[1582],{"id":1583,"sortIndex":21,"affiliation":1584,"properties":20},"78627eea-9738-4a81-9717-f6c0c3a6d72b",{"id":1583,"createTime":20,"updateTime":20,"relativeEntities":1585,"slug":20,"properties":1586,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1589,"statistic":20},[],{"title":1587},{"VI":1588},"University of Arizona Cancer Center, Tucson, USA",[],{"title":1591},{"VI":1592},"Thomas P. Miller",{"id":1594,"sortIndex":143,"researcher":20,"roles":1595,"affiliations":1596,"properties":1605},"2eafca2a-0b6b-45fe-a722-3d1d7fee93c6",[980],[1597],{"id":1598,"sortIndex":21,"affiliation":1599,"properties":20},"302eac76-185e-4a5d-9402-64232948f555",{"id":1598,"createTime":20,"updateTime":20,"relativeEntities":1600,"slug":20,"properties":1601,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1604,"statistic":20},[],{"title":1602},{"VI":1603},"Wichita CCOP, Wichita, USA",[],{"title":1606},{"VI":1607},"Shaker R. Dakhil",{"url":1513,"publisher":1609,"properties":1659},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1610,"slug":10,"properties":1611,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1615,"manageAffiliations":1628,"indexDatabases":1639,"url":94,"thumbnailPath":20,"statistic":1654,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":1612,"title":1613,"eissn":1614},{"VOID":13},{"EN":15},{"VOID":17},[1616,1620,1624],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1617,"label":1618,"description":1619,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1621,"label":1622,"description":1623,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1625,"label":1626,"description":1627,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[1629,1634],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":1630,"slug":20,"properties":1631,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1633,"statistic":20},[],{"title":1632},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":1635,"slug":20,"properties":1636,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1638,"statistic":20},[],{"title":1637},{"EN":54},[],[1640,1647],{"id":58,"indexDatabase":1641,"url":71,"indexYears":20,"academicFieldIds":1646,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":1642,"label":1643,"description":1644,"key":67,"publicationTags":1645,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":1648,"url":87,"indexYears":88,"academicFieldIds":1653,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":1649,"label":1650,"description":1651,"key":84,"publicationTags":1652,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":1655,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":1656,"totalCitation":21,"totalCitationByYear":1657,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1658,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":1660,"volume":1662},{"VOID":1661},"259-261",{"VOID":1663},"12","1994-09-01",1994,[69,93],{"id":1668,"createTime":1669,"updateTime":1670,"relativeEntities":1671,"slug":1672,"properties":1673,"entityType":972,"verifyStatus":127,"verifyTime":1670,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1682,"fullTextUrl":1683,"authors":1684,"publicationType":1060,"publisherRelationship":1794,"citationCount":20,"citationInfo":20,"publishDate":1852,"publishYear":1853,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":1854,"openAccess":20,"references":20,"isForceReanalyzing":1120},"016481c5-341e-4a4a-909c-94d09873dc40","2024-01-10T11:53:30.534+00:00","2024-12-27T18:24:14.974+00:00",[],"Ipilimumab-associated-hepatitis-imaging-and-clinicopathologic-findings",{"abstract":1674,"title":1676,"references":1678,"doi":1680},{"EN":1675},"Ipilimumab is a novel immunomodulator demonstrating promising efficacy in treatment of melanoma and other cancers. The clinical benefit from ipilimumab can be hampered by the immure-related adverse events (irAEs) caused by dysregulation of host immune system. Ipilimumab associated hepatitis is also an important irAE, however, there have been limited descriptions of its clinicopathologic and imaging characteristics. We aim to describe the clinicopathologic and imaging characteristics of 6 patients who were diagnosed as ipilimumab associated hepatitis during the ipilimumab treatment for melanoma. The clinical features of these patients were as follows: (1) severe cases with systemic symptoms and highly increased level of liver function tests (LFTs), and (2) mild asymptomatic cases with mildly increased level of LFTs. In severe cases with ALT >1,000 IU\u002FL, imaging findings were characterized by mild hepatomegaly, periportal edema, and periportal lymphadenopathy, while mild cases showed normal imaging findings. This spectrum of imaging findings in our series was similar to that of common causes of acute hepatitis. Among 3 cases with pathologic specimen, two cases showed severe panlobular hepatitis with prominent perivenular infiltrate with endothelialitis, suggestive of predominant injury to hepatocytes, while the other case showed mild portal mononuclear infiltrate around proliferated bile ductules, suggestive of predominant injury to bile ducts. In summary, ipilimumab associated hepatitis may demonstrate variable imaging findings according to its clinical severity, and histologically may manifest either as a predominant injury to hepatocytes (acute hepatitis pattern) or as a predominant injury to bile ducts (biliary pattern).",{"EN":1677},"Ipilimumab associated hepatitis: imaging and clinicopathologic findings",{"VOID":1679},"citation_journal_title=N Engl J Med; citation_title=Improved survival with ipilimumab in patients with metastatic melanoma; citation_author=FS Hodi, SJ O’Day, DF McDermott; citation_volume=363; citation_issue=8; citation_publication_date=2010; citation_pages=711-723; citation_doi=10.1056\u002FNEJMoa1003466; citation_id=CR1\ncitation_journal_title=Semin Oncol; citation_title=Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy; citation_author=A Hoos, R Ibrahim, A Korman; citation_volume=37; citation_issue=5; citation_publication_date=2010; citation_pages=533-546; citation_doi=10.1053\u002Fj.seminoncol.2010.09.015; citation_id=CR2\ncitation_journal_title=AJR Am J Roentgenol; citation_title=Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy; citation_author=KN O’Regan, JP Jagannathan, N Ramaiya, FS Hodi; citation_volume=197; citation_issue=2; citation_publication_date=2011; citation_pages=W241-W246; citation_doi=10.2214\u002FAJR.10.6032; citation_id=CR3\nWeber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. doi:\n                    10.1200\u002FJCO.2012.41.6750\n                    \n                  \n                \ncitation_journal_title=Semin Oncol; citation_title=The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications; citation_author=AM Giacomo, M Biagioli, M Maio; citation_volume=37; citation_issue=5; citation_publication_date=2010; citation_pages=499-507; citation_doi=10.1053\u002Fj.seminoncol.2010.09.007; citation_id=CR5\ncitation_journal_title=Clin Nucl Med; citation_title=Ipilimumab-induced colitis on FDG PET\u002FCT; citation_author=A Lyall, HA Vargas, RD Carvajal, G Ulaner; citation_volume=37; citation_issue=6; citation_publication_date=2012; citation_pages=629-630; citation_doi=10.1097\u002FRLU.0b013e318248549a; citation_id=CR6\ncitation_journal_title=AJR Am J Roentgenol; citation_title=Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy; citation_author=Y Bronstein, CS Ng, P Hwu, WJ Hwu; citation_volume=197; citation_issue=6; citation_publication_date=2011; citation_pages=W992-W1000; citation_doi=10.2214\u002FAJR.10.6198; citation_id=CR7\ncitation_journal_title=Radiographics; citation_title=The infected liver: radiologic-pathologic correlation; citation_author=KJ Mortele, E Segatto, PR Ros; citation_volume=24; citation_issue=4; citation_publication_date=2004; citation_pages=937-955; citation_doi=10.1148\u002Frg.244035719; citation_id=CR8\ncitation_journal_title=Dig Dis Sci; citation_title=Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma; citation_author=DE Kleiner, D Berman; citation_volume=57; citation_issue=8; citation_publication_date=2012; citation_pages=2233-2240; citation_doi=10.1007\u002Fs10620-012-2140-5; citation_id=CR9\ncitation_journal_title=Proc Natl Acad Sci U S A; citation_title=Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma; citation_author=GQ Phan, JC Yang, RM Sherry; citation_volume=100; citation_issue=14; citation_publication_date=2003; citation_pages=8372-8377; citation_doi=10.1073\u002Fpnas.1533209100; citation_id=CR10\ncitation_journal_title=Ann Oncol; citation_title=Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study; citation_author=SJ O’Day, M Maio, V Chiarion-Sileni; citation_volume=21; citation_issue=8; citation_publication_date=2010; citation_pages=1712-1717; citation_doi=10.1093\u002Fannonc\u002Fmdq013; citation_id=CR11\ncitation_journal_title=J Clin Oncol; citation_title=Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy; citation_author=KD Chmiel, D Suan, C Liddle; citation_volume=29; citation_issue=9; citation_publication_date=2011; citation_pages=e237-e240; citation_doi=10.1200\u002FJCO.2010.32.2206; citation_id=CR12\ncitation_journal_title=Immunol Rev; citation_title=Twelve immunotherapy drugs that could cure cancers; citation_author=MA Cheever; citation_volume=222; citation_publication_date=2008; citation_pages=357-368; citation_doi=10.1111\u002Fj.1600-065X.2008.00604.x; citation_id=CR13",{"VOID":1681},"10.1007\u002Fs10637-013-9939-6","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10637-013-9939-6","https:\u002F\u002Flink.springer.com\u002Fcontent\u002Fpdf\u002F10.1007\u002Fs10637-013-9939-6.pdf",[1685,1709,1722,1735,1748,1761,1779],{"id":1686,"sortIndex":21,"researcher":20,"roles":1687,"affiliations":1688,"properties":1706},"6cd24042-dd57-404c-9f92-059c8abb8824",[980],[1689,1697],{"id":1690,"sortIndex":21,"affiliation":1691,"properties":20},"782705dd-e831-4cef-bd99-4fed575af0a9",{"id":1690,"createTime":20,"updateTime":20,"relativeEntities":1692,"slug":20,"properties":1693,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1696,"statistic":20},[],{"title":1694},{"VI":1695},"Department of Imaging, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA",[],{"id":1698,"sortIndex":99,"affiliation":1699,"properties":1705},"3b43e3b0-6f8f-4e2f-9dd6-3c644f22e300",{"id":1698,"createTime":20,"updateTime":20,"relativeEntities":1700,"slug":20,"properties":1701,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1704,"statistic":20},[],{"title":1702},{"VI":1703},"Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Seoul Asan Medical Center, Seoul, Korea",[],{},{"title":1707},{"VI":1708},"Kim, Kyung Won",{"id":1710,"sortIndex":99,"researcher":20,"roles":1711,"affiliations":1712,"properties":1719},"a93bf9bc-2989-4812-bce2-7de8ccfefdc8",[980],[1713],{"id":1690,"sortIndex":21,"affiliation":1714,"properties":20},{"id":1690,"createTime":20,"updateTime":20,"relativeEntities":1715,"slug":20,"properties":1716,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1718,"statistic":20},[],{"title":1717},{"VI":1695},[],{"title":1720},{"VI":1721},"Ramaiya, Nikhil H.",{"id":1723,"sortIndex":100,"researcher":20,"roles":1724,"affiliations":1725,"properties":1732},"c537cbdb-d343-4a00-b48d-5f7bed5f016e",[980],[1726],{"id":1690,"sortIndex":21,"affiliation":1727,"properties":20},{"id":1690,"createTime":20,"updateTime":20,"relativeEntities":1728,"slug":20,"properties":1729,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1731,"statistic":20},[],{"title":1730},{"VI":1695},[],{"title":1733},{"VI":1734},"Krajewski, Katherine M.",{"id":1736,"sortIndex":101,"researcher":20,"roles":1737,"affiliations":1738,"properties":1745},"3bf929f9-6e38-4920-88da-668ed35acaac",[980],[1739],{"id":1690,"sortIndex":21,"affiliation":1740,"properties":20},{"id":1690,"createTime":20,"updateTime":20,"relativeEntities":1741,"slug":20,"properties":1742,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1744,"statistic":20},[],{"title":1743},{"VI":1695},[],{"title":1746},{"VI":1747},"Jagannathan, Jyothi P.",{"id":1749,"sortIndex":142,"researcher":20,"roles":1750,"affiliations":1751,"properties":1758},"479f53ee-e0c3-4c57-95bb-e4496c2c8d2b",[980],[1752],{"id":1690,"sortIndex":21,"affiliation":1753,"properties":20},{"id":1690,"createTime":20,"updateTime":20,"relativeEntities":1754,"slug":20,"properties":1755,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1757,"statistic":20},[],{"title":1756},{"VI":1695},[],{"title":1759},{"VI":1760},"Tirumani, Sree Harsha",{"id":1762,"sortIndex":143,"researcher":20,"roles":1763,"affiliations":1764,"properties":1776},"ce975b30-e843-4a7c-bf6c-bd52018dfd15",[980],[1765],{"id":1766,"sortIndex":21,"affiliation":1767,"properties":1773},"5a851db9-55ea-4462-a508-fdc91bac6359",{"id":1766,"createTime":20,"updateTime":20,"relativeEntities":1768,"slug":20,"properties":1769,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1772,"statistic":20},[],{"title":1770},{"EN":1771},"Department of Pathology, Brigham and Women's Hospital, Boston, United States;",[],{"title":1774},{"VI":1775},"Department of Pathology, Brigham and Women’s Hospital, Boston, USA",{"title":1777},{"VI":1778},"Srivastava, Amitabh",{"id":1780,"sortIndex":145,"researcher":20,"roles":1781,"affiliations":1782,"properties":1791},"9ff44235-56e7-4fbf-90e9-0236beabf369",[980],[1783],{"id":1784,"sortIndex":21,"affiliation":1785,"properties":20},"18b5b7b6-72e7-4261-a70b-08e3be723ad3",{"id":1784,"createTime":20,"updateTime":20,"relativeEntities":1786,"slug":20,"properties":1787,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1790,"statistic":20},[],{"title":1788},{"VI":1789},"Department of Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA",[],{"title":1792},{"VI":1793},"Ibrahim, Nageatte",{"url":1682,"publisher":1795,"properties":1845},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1796,"slug":10,"properties":1797,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1801,"manageAffiliations":1814,"indexDatabases":1825,"url":94,"thumbnailPath":20,"statistic":1840,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":1798,"title":1799,"eissn":1800},{"VOID":13},{"EN":15},{"VOID":17},[1802,1806,1810],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1803,"label":1804,"description":1805,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1807,"label":1808,"description":1809,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1811,"label":1812,"description":1813,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[1815,1820],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":1816,"slug":20,"properties":1817,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1819,"statistic":20},[],{"title":1818},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":1821,"slug":20,"properties":1822,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1824,"statistic":20},[],{"title":1823},{"EN":54},[],[1826,1833],{"id":58,"indexDatabase":1827,"url":71,"indexYears":20,"academicFieldIds":1832,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":1828,"label":1829,"description":1830,"key":67,"publicationTags":1831,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":1834,"url":87,"indexYears":88,"academicFieldIds":1839,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":1835,"label":1836,"description":1837,"key":84,"publicationTags":1838,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":1841,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":1842,"totalCitation":21,"totalCitationByYear":1843,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1844,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"issue":1846,"pages":1848,"volume":1850},{"VOID":1847},"4",{"VOID":1849},"1071-1077",{"VOID":1851},"31","2013-08-01",2013,[69,93],{"id":1856,"createTime":1857,"updateTime":1858,"relativeEntities":1859,"slug":1860,"properties":1861,"entityType":972,"verifyStatus":127,"verifyTime":1858,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1870,"fullTextUrl":20,"authors":1871,"publicationType":1060,"publisherRelationship":1916,"citationCount":20,"citationInfo":20,"publishDate":1972,"publishYear":1973,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":1974,"openAccess":20,"references":20,"isForceReanalyzing":1120},"01a4a9a0-866a-4639-9dbf-c4ac3d23e4ab","2024-01-14T15:37:07.125+00:00","2025-01-18T13:16:42.541+00:00",[],"The-DAC-system-and-associations-with-multiple-myeloma",{"abstract":1862,"title":1864,"references":1866,"doi":1868},{"EN":1863},"Despite the clear progress achieved in recent years in the treatment of MM, most patients eventually relapse and therefore novel therapeutic options are still necessary for these patients. In this regard, several drugs that target specific mechanisms of the tumor cells are currently being explored in the preclinical and clinical setting. This manuscripts offers a review of the rationale and current status of the antimyeloma activity of one of the most relevant examples of these targeted drugs: deacetylase inhibitors (DACi). Several studies have demonstrated the prooncogenic activity of deacetylases (DACs) through the targeting not only of histones but also of non histone proteins relevant to tumor progression, such as p53, E2F family members, Bcl-6, Hsp90, HIF-1α or Nur77. This fact together with the DACs overexpression present in several tumors, has prompted the development of some DACi with potential antitumor effect. This situation is also evident in the case of MM as two mechanisms of DACi, the inhibition of the epigenetic inactivation of p53 and the blockade of the unfolded protein response, through the inhibition of the aggressome formation (by targeting DAC6) and the inactivation of the chaperone system (by acetylating HSP-90), provides the rationale for the exploration of the potential antimyeloma activity of these compounds. Several DACi with different chemical structure and different selectivity for targeting the DAC families have been tested in MM. Their preclinical activity in monotherapy has been quite exciting and has been described to be mediated by various mechanisms: the induction of apoptosis and cell cycle arrest mainly by the upregulation of p21; the interferece with the interaction between plasma cells and the microenvironment, by reducing the expression and signalling of several cytokines or by inhibiting angiogenesis. Finally they also have a role in protecting murine models from myeloma bone disease. Neverteless, the clinical activity in monotherapy of these drugs in relapsed\u002Frefractory MM patients has been very modest. This has prompted the development of combinations such as the one with bortezomib or lenalidomide and dexamethasone, which have already been taken into the clinics with positive preliminary results.",{"EN":1865},"The DAC system and associations with multiple myeloma",{"VOID":1867},"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873\nPetrelli NJ, Winer EP, Brahmer J et al (2009) Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol 27:6052–6069\nKyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962–2972\nKumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520\nRichardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498\nSinghal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571\nDimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132\nWeber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142\nOcio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF (2008) New drugs in multiple myeloma: mechanisms of action and phase I\u002FII clinical findings. Lancet Oncol 9:1157–1165\nMitsiades CS, Hideshima T, Chauhan D et al (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 46:166–175\nGregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17–31\nDokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981–989\nde Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749\nWitt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277:8–21\nBolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784\nMinucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51\nXu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541–5552\nHubbert C, Guardiola A, Shao R et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455–458\nTran AD, Marmo TP, Salam AA et al (2007) HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 120:1469–1479\nBali P, Pranpat M, Bradner J et al (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729–26734\nEsteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159\nWeichert W, Roske A, Gekeler V et al (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9:139–148\nWeichert W, Roske A, Niesporek S et al (2008) Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14:1669–1677\nWeichert W, Roske A, Gekeler V et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604–610\nMarks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202\nOzdag H, Teschendorff AE, Ahmed AA et al (2006) Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7:90\nSakuma T, Uzawa K, Onda T et al (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29:117–124\nSaji S, Kawakami M, Hayashi S et al (2005) Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24:4531–4539\nZhang Z, Yamashita H, Toyama T et al (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10:6962–6968\nLinggi BE, Brandt SJ, Sun ZW, Hiebert SW (2005) Translating the histone code into leukemia. J Cell Biochem 96:938–950\nChoi Y, Elagib KE, Goldfarb AN (2005) AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein. Crit Rev Eukaryot Gene Expr 15:207–216\nAmann JM, Nip J, Strom DK et al (2001) ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21:6470–6483\nAtsumi A, Tomita A, Kiyoi H, Naoe T (2006) Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 345:1471–1480\nChauchereau A, Mathieu M, de Saintignon SJ et al (2004) HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene 23:8777–8784\nXiong W, Wu X, Starnes S et al (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112:4235–4246\nGutierrez NC, Castellanos MV, Martin ML et al (2007) Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21:143–150\nChang H, Qi C, Yi QL, Reece D, Stewart AK (2005) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105:358–360\nChng WJ, Price-Troska T, Gonzalez-Paz N et al (2007) Clinical significance of TP53 mutation in myeloma. Leukemia 21:582–584\nOcio EM, Maiso P, Chen X et al (2009) Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113:3781–3791\nHurt EM, Thomas SB, Peng B, Farrar WL (2006) Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 5:1154–1160\nDavenport EL, Moore HE, Dunlop AS et al (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 110:2641–2649\nDavenport EL, Morgan GJ, Davies FE (2008) Untangling the unfolded protein response. Cell Cycle 7:865–869\nBennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17:351–365\nKopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524–530\nKawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738\nMiller TA, Witter DJ, Belvedere S (2003) Histone deacetylase inhibitors. J Med Chem 46:5097–5116\nRasheed WK, Johnstone RW, Prince HM (2007) Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16:659–678\nHaggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100:4389–4394\nMitsiades N, Mitsiades CS, Richardson PG et al (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101:4055–4062\nMitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540–545\nLavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68:170–178\nCatley L, Weisberg E, Tai YT et al (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102:2615–2622\nKhan SB, Maududi T, Barton K, Ayers J, Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125:156–161\nKaiser M, Zavrski I, Sterz J et al (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91:248–251\nSchwartz C, Palissot V, Aouali N et al (2007) Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 30:573–582\nKitazoe K, Abe M, Hiasa M et al (2009) Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol 89:45–57\nNeri P, Tagliaferri P, Di Martino MT et al (2008) In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 143:520–531\nCatley L, Weisberg E, Kiziltepe T et al (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108:3441–3449\nMaiso P, Carvajal-Vergara X, Ocio EM et al (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781–5789\nOcio EM, Vilanova D, Atadja P et al (2009) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica\nFeng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S (2007) The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 139:385–397\nArts J, Angibaud P, Marien A et al (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97:1344–1353\nFeng R, Ma H, Hassig CA et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 7:1494–1505\nDeleu S, Lemaire M, Arts J et al (2009) The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 23:1894–1903\nTodoerti K, Barbui V, Pedrini O et al Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 95:260–269\nMandl-Weber S, Meinel F, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol\nFandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7:646–657\nAkiyama M, Hideshima T, Hayashi T et al (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62:3876–3882\nChen S, Dai Y, Pei XY, Grant S (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29:6149–6169\nDamiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658–1667\nHideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585–598\nWolf JL, Siegel D, Matous J et al (2008) A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. ASH Annu Meet Abstr 112:2774\nRichardson P, Mitsiades C, Colson K et al (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49:502–507\nGalli M, Salmoiraghi S, Golay J et al A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 89:185–190\nNiesvizky R, Ely S, DiLiberto M et al (2005) Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM). ASH Annu Meet Abstr 106:2574-\nCampbell RA, Sanchez E, Steinberg J et al Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 84:201–211\nDeleu S, Lemaire M, Arts J et al (2009) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69:5307–5311\nHideshima T, Bradner JE, Wong J et al (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567–8572\nPei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839–3852\nBadros A, Burger AM, Philip S et al (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15:5250–5257\nWeber D, Badros AZ, Jagannath S et al (2008) Vorinostat plus bortezomib for the treatment of relapsed\u002Frefractory multiple myeloma: early clinical experience. ASH Annu Meet Abstr 112:871\nWeber DM, Jagannath S, Sobecks R et al (2008) Combination of vorinostat plus bortezomib for the treatment of patients with multiple myeloma who have previously received bortezomib. ASH Annu Meet Abstr 112:3711\nSan-Miguel JF, Sezer O, Siegel D et al (2009) A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma. ASH Annu Meet Abstr 114:3852-\nHarrison SJ, Quach H, Yuen K et al (2008) High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I\u002FII clinical trial. ASH Annu Meet Abstr 112:3698\nVoorhees PM, Gasparetto C, Richards KL et al (2009) Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed\u002Frefractory multiple myeloma: results of a phase I study. ASH Annu Meet Abstr 114:306-\nSpencer A, Lonial S, Taylor K et al (2009) Panobinostat and lenalidomide combination phase I trial in myeloma. Clin Lymphoma Myeloma. Abstract 329\nSiegel D, Weber DM, Mitsiades CS et al (2009) Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a phase I study. ASH Annu Meet Abstr 114:305-\nBerenson JR, Yellin O, Boccia RV, Nassir Y, Rothstein S, Swift RA (2009) A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). ASH Annu Meet Abstr 114:1855-",{"VOID":1869},"10.1007\u002Fs10637-010-9589-x","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10637-010-9589-x",[1872,1896],{"id":1873,"sortIndex":21,"researcher":20,"roles":1874,"affiliations":1875,"properties":1893},"ec766b5f-a51c-4c89-a354-c254cf32df48",[980],[1876,1884],{"id":1877,"sortIndex":21,"affiliation":1878,"properties":20},"82346293-bfa9-4c32-a7fd-60bbdcc875c8",{"id":1877,"createTime":20,"updateTime":20,"relativeEntities":1879,"slug":20,"properties":1880,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1883,"statistic":20},[],{"title":1881},{"VI":1882},"University Hospital of Salamanca, Salamanca, Spain",[],{"id":1885,"sortIndex":99,"affiliation":1886,"properties":1892},"1758167b-478c-4a19-a854-34e6795aefab",{"id":1885,"createTime":20,"updateTime":20,"relativeEntities":1887,"slug":20,"properties":1888,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1891,"statistic":20},[],{"title":1889},{"VI":1890},"IBMCC-CSIC (Institute of Molecular and Cellular Biology of Cancer-Spanish National Research Council) Cancer Research Center, University of Salamanca, Salamanca, Spain",[],{},{"title":1894},{"VI":1895},"Enrique M. Ocio",{"id":1897,"sortIndex":99,"researcher":20,"roles":1898,"affiliations":1899,"properties":1913},"22e5cdbb-2cef-4c2e-9496-acf647fd5c4e",[980],[1900,1906],{"id":1877,"sortIndex":21,"affiliation":1901,"properties":20},{"id":1877,"createTime":20,"updateTime":20,"relativeEntities":1902,"slug":20,"properties":1903,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1905,"statistic":20},[],{"title":1904},{"VI":1882},[],{"id":1885,"sortIndex":99,"affiliation":1907,"properties":1912},{"id":1885,"createTime":20,"updateTime":20,"relativeEntities":1908,"slug":20,"properties":1909,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1911,"statistic":20},[],{"title":1910},{"VI":1890},[],{},{"title":1914},{"VI":1915},"Jesús F. San Miguel",{"url":1870,"publisher":1917,"properties":1967},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1918,"slug":10,"properties":1919,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1923,"manageAffiliations":1936,"indexDatabases":1947,"url":94,"thumbnailPath":20,"statistic":1962,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":1920,"title":1921,"eissn":1922},{"VOID":13},{"EN":15},{"VOID":17},[1924,1928,1932],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1925,"label":1926,"description":1927,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1929,"label":1930,"description":1931,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1933,"label":1934,"description":1935,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[1937,1942],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":1938,"slug":20,"properties":1939,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1941,"statistic":20},[],{"title":1940},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":1943,"slug":20,"properties":1944,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1946,"statistic":20},[],{"title":1945},{"EN":54},[],[1948,1955],{"id":58,"indexDatabase":1949,"url":71,"indexYears":20,"academicFieldIds":1954,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":1950,"label":1951,"description":1952,"key":67,"publicationTags":1953,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":1956,"url":87,"indexYears":88,"academicFieldIds":1961,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":1957,"label":1958,"description":1959,"key":84,"publicationTags":1960,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":1963,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":1964,"totalCitation":21,"totalCitationByYear":1965,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1966,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":1968,"volume":1970},{"VOID":1969},"28-35",{"VOID":1971},"28","2010-12-01",2010,[69,93],{"id":1976,"createTime":1977,"updateTime":1978,"relativeEntities":1979,"slug":1980,"properties":1981,"entityType":972,"verifyStatus":127,"verifyTime":1978,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1990,"fullTextUrl":20,"authors":1991,"publicationType":1060,"publisherRelationship":2245,"citationCount":20,"citationInfo":20,"publishDate":2301,"publishYear":1498,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":2302,"openAccess":20,"references":20,"isForceReanalyzing":1120},"01c08901-105d-4d19-a9cb-9bcd39a59f40","2023-12-06T12:02:54.698+00:00","2025-02-08T00:18:55.726+00:00",[],"An-open-label-single-arm-phase-2-study-of-the-Aurora-kinase-A-inhibitor-alisertib-in-patients-with-advanced-urothelial-cancer",{"abstract":1982,"title":1984,"references":1986,"doi":1988},{"EN":1983},"\n                        Background Progress in developing effective salvage therapies for UC is warranted. Alisertib is an orally available, selective inhibitor of the aurora kinase A. Methods A single-group, phase 2 trial was conducted with alisertib 50 mg orally BID for 7 days, with 14d rest until disease progression (PD) (NCT02109328). The primary endpoint (EP) was RECIST 1.1 objective response-rate (ORR, H0 ≤ 5 %, H1 ≥ 20 %, α = 10 % and β = 20 %). Eligibility included failure of at least one platinum-based regimen. Results From 10\u002F2014 to 04\u002F2015, 22 patients were enrolled (20 evaluable for response), 8 (36.4 %) in second-line and 14 (63.6 %) beyond the second-line. Eight (36.4 %) had an ECOG-performance status 1–2. Two partial responses (PR, ORR: 9.1 %), 7 stable disease (SD) and 11 PD were obtained. Median follow-up was 8.3 months (IQR: 7–10.3), 6-month progression-free survival (PFS) was 13.6 % (95%CI: 4.8–39.0). Two SD are still receiving treatment after 11.5 and 6.3 months. Median overall survival (OS) was not reached (6-month OS: 59.1 %, 95%CI: 41.7–83.7). Hb \u003C 10 g\u002Fdl was significantly associated with shorter PFS and OS multivariably (p = 0.031 and p = 0.033). Tissue of the case with 11.5 month SD harbored a missense mutation of mTOR (E1813D), the nonsense mutation Q527STOP of TSC1, HER3 and TAF1L missense mutations. Grade 3–4 adverse events (AE) were: 40.9 % mucositis, 36.4 % fatigue, 18.2 % neutropenia (13.6 % febrile neutropenia). There were 2 treatment-related deaths. Conclusions The study did not meet the primary EP, yet sustained disease control was obtained in about 14 % of patients. The incidence of AE and the issue of patient selection are two major concerns.",{"EN":1985},"An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer",{"VOID":1987},"Powles T, Eder JP, Fine GD, et al. (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562\nPlimack ER, Bellmunt J, Gupta S, et al. (2015) Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33 (suppl; abstr 4502).\nPetrylak DP, Powles T, Bellmunt J, et al. (2015) A phase Is study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 33 (suppl; abstr 4501).\nRosenberg J, Petrylak D, Abidoye O, et al. (2015) (21LBA) Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210). Eur J Cancer 51(Supplement 3):S720\nSonpavde G, Jones BS, Bellmunt J, et al. (2015) Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am 29:361–376\nRaggi D, Miceli R, Sonpavde G, et al. (2015) Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. doi:10.1093\u002Fannonc\u002Fmdv509\nSonpavde G, Pond GR, Choueiri TK, et al. (2015) Single agent taxane versus taxane containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol. doi:10.1016\u002Fj.eururo.2015.07.042\nSen S, Zhou H, Zhang RD, et al. (2002) Amplification\u002Foverexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320–1329\nZhou N, Singh K, Mir MC, et al. (2013) The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell cycle progression in bladder cancer cells in vitro and in vivo. Clin Cancer Res 19:1717–1728\nCervantes A, Elez E, Desamparados R, et al. (2012) Phase I pharmacokinetic\u002Fpharmacodynamic study of MLN8237, an investigational, oral, selective Aurora A kinase inhibitor, in aptients with advanced solid tumors. Clin Cancer Res 18:4764–4774\nEisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247\nYoung H, Baum R, Cremerius U, et al. (1999) Measurement of clinical and subclinical tumour response using (18F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for the research and treatment of cancer (EORTC) PET study group. Eur J Cancer 35:1773–1782\nMelichar B, Adenis A, Lockhart AC, et al. (2015) Safety and activity of alisertib, an investigational Aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, and gastro-oesophageal adenocarcinoma: five-arm phase 2 study. Lancet Oncol 16:395–405\nBarr PM, Li H, Spier C, et al. (2015) Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol 33:2399–2404\nFriedberg JW, Mahadevan D, Cebula E, et al. (2013) Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 32:44–50\nMatulonis UA, Sharma S, Ghamande S, et al. (2012) Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127:63–69\nStadler WM, Vaughn DJ, Sonpavde G, et al. (2014) An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120:976–982\nBellmunt J, Choueiry TK, Fougeray R, et al. (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850–1855\nSonpavde G, Pond GR, Fougeray R, et al. (2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63:717–723\nSonpavde G, Pond GR, Rosenberg JE, et al. (2015) Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. doi:10.1016\u002Fj.juro.2015.07.111\nIyer G, Hanrahan AJ, Milowsky MI, et al. (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221\nWagle N, Grabiner BC, Van Allen EM, et al. (2014) Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 4:546–553\nTentler JJ, Iokina AA, Tan AC, et al. (2015) p53 family members regulate phenotypic response to Aurora kinase A inhibition in triple-negative breast cancer. Mol Cancer Ther 14:1117–1129\nMarxer M, Ma HT, Poon RYC (2014) p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Oncogene 33:3550–3560\nTabernero J, Bahleda R, Dientsmann R, et al. (2015) Phase I dose escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 33:3401–3408",{"VOID":1989},"10.1007\u002Fs10637-016-0328-9","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10637-016-0328-9",[1992,2007,2022,2035,2048,2061,2076,2091,2106,2121,2136,2149,2162,2184,2199,2212,2225],{"id":1993,"sortIndex":21,"researcher":20,"roles":1994,"affiliations":1995,"properties":2004},"ddb4ac64-c3ca-4dd0-b2a1-e08b53a86abd",[980],[1996],{"id":1997,"sortIndex":21,"affiliation":1998,"properties":20},"72d2c385-4ee7-410c-b6fa-224e64865629",{"id":1997,"createTime":20,"updateTime":20,"relativeEntities":1999,"slug":20,"properties":2000,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2003,"statistic":20},[],{"title":2001},{"VI":2002},"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2005},{"VI":2006},"Andrea Necchi",{"id":2008,"sortIndex":99,"researcher":20,"roles":2009,"affiliations":2010,"properties":2019},"3e919c7b-808c-45ba-9788-ac11e7230b0f",[980],[2011],{"id":2012,"sortIndex":21,"affiliation":2013,"properties":20},"51a4c231-32d5-4707-9b2b-f63fc9b38387",{"id":2012,"createTime":20,"updateTime":20,"relativeEntities":2014,"slug":20,"properties":2015,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2018,"statistic":20},[],{"title":2016},{"VI":2017},"Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2020},{"VI":2021},"Salvatore Lo Vullo",{"id":2023,"sortIndex":100,"researcher":20,"roles":2024,"affiliations":2025,"properties":2032},"97c23d23-ff21-42d5-9ca8-d8bbe5e0ad04",[980],[2026],{"id":2012,"sortIndex":21,"affiliation":2027,"properties":20},{"id":2012,"createTime":20,"updateTime":20,"relativeEntities":2028,"slug":20,"properties":2029,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2031,"statistic":20},[],{"title":2030},{"VI":2017},[],{"title":2033},{"VI":2034},"Luigi Mariani",{"id":2036,"sortIndex":101,"researcher":20,"roles":2037,"affiliations":2038,"properties":2045},"48cc573a-50a1-44d7-9c6a-b5052231ff23",[980],[2039],{"id":1997,"sortIndex":21,"affiliation":2040,"properties":20},{"id":1997,"createTime":20,"updateTime":20,"relativeEntities":2041,"slug":20,"properties":2042,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2044,"statistic":20},[],{"title":2043},{"VI":2002},[],{"title":2046},{"VI":2047},"Daniele Raggi",{"id":2049,"sortIndex":142,"researcher":20,"roles":2050,"affiliations":2051,"properties":2058},"f99eda21-3b23-48ff-98a0-aca4330acd11",[980],[2052],{"id":1997,"sortIndex":21,"affiliation":2053,"properties":20},{"id":1997,"createTime":20,"updateTime":20,"relativeEntities":2054,"slug":20,"properties":2055,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2057,"statistic":20},[],{"title":2056},{"VI":2002},[],{"title":2059},{"VI":2060},"Patrizia Giannatempo",{"id":2062,"sortIndex":143,"researcher":20,"roles":2063,"affiliations":2064,"properties":2073},"eff4d527-8249-4c04-943f-f5c20543c6c5",[980],[2065],{"id":2066,"sortIndex":21,"affiliation":2067,"properties":20},"6734d588-3020-4ccc-8d62-c92b7f824f60",{"id":2066,"createTime":20,"updateTime":20,"relativeEntities":2068,"slug":20,"properties":2069,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2072,"statistic":20},[],{"title":2070},{"EN":2071},"Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2074},{"VI":2075},"Giuseppina Calareso",{"id":2077,"sortIndex":145,"researcher":20,"roles":2078,"affiliations":2079,"properties":2088},"a776571a-745e-42e7-a9d3-ad2bbc71f210",[980],[2080],{"id":2081,"sortIndex":21,"affiliation":2082,"properties":20},"78c35a2a-4b32-434a-8acd-f866b9cdaa3c",{"id":2081,"createTime":20,"updateTime":20,"relativeEntities":2083,"slug":20,"properties":2084,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2087,"statistic":20},[],{"title":2085},{"VI":2086},"Pharmacy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2089},{"VI":2090},"Elena Togliardi",{"id":2092,"sortIndex":146,"researcher":20,"roles":2093,"affiliations":2094,"properties":2103},"c8e547fa-c524-4dcb-806a-fc9c1afb96ed",[980],[2095],{"id":2096,"sortIndex":21,"affiliation":2097,"properties":20},"8f457fd0-7337-4759-9a7d-6d3d14f7392d",{"id":2096,"createTime":20,"updateTime":20,"relativeEntities":2098,"slug":20,"properties":2099,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2102,"statistic":20},[],{"title":2100},{"VI":2101},"Nuclear Medicine and PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2104},{"VI":2105},"Flavio Crippa",{"id":2107,"sortIndex":451,"researcher":20,"roles":2108,"affiliations":2109,"properties":2118},"494abd7a-5307-4aec-b078-b9fa20fac344",[980],[2110],{"id":2111,"sortIndex":21,"affiliation":2112,"properties":20},"39fe6edb-1d37-4934-9f94-8da190efb4df",{"id":2111,"createTime":20,"updateTime":20,"relativeEntities":2113,"slug":20,"properties":2114,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2117,"statistic":20},[],{"title":2115},{"VI":2116},"Clinical Trials Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2119},{"VI":2120},"Nicola Di Genova",{"id":2122,"sortIndex":240,"researcher":20,"roles":2123,"affiliations":2124,"properties":2133},"14bb28e4-a536-490b-a656-05e94024406f",[980],[2125],{"id":2126,"sortIndex":21,"affiliation":2127,"properties":20},"74e54771-2e5c-4951-94c1-e87a2801d10c",{"id":2126,"createTime":20,"updateTime":20,"relativeEntities":2128,"slug":20,"properties":2129,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2132,"statistic":20},[],{"title":2130},{"VI":2131},"Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2134},{"VI":2135},"Federica Perrone",{"id":2137,"sortIndex":299,"researcher":20,"roles":2138,"affiliations":2139,"properties":2146},"6fe3c99c-fbd2-4252-a827-33ed16c8d233",[980],[2140],{"id":2126,"sortIndex":21,"affiliation":2141,"properties":20},{"id":2126,"createTime":20,"updateTime":20,"relativeEntities":2142,"slug":20,"properties":2143,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2145,"statistic":20},[],{"title":2144},{"VI":2131},[],{"title":2147},{"VI":2148},"Maurizio Colecchia",{"id":2150,"sortIndex":144,"researcher":20,"roles":2151,"affiliations":2152,"properties":2159},"51717055-a4c9-4930-bae4-2d2ad68cee93",[980],[2153],{"id":2126,"sortIndex":21,"affiliation":2154,"properties":20},{"id":2126,"createTime":20,"updateTime":20,"relativeEntities":2155,"slug":20,"properties":2156,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2158,"statistic":20},[],{"title":2157},{"VI":2131},[],{"title":2160},{"VI":2161},"Biagio Paolini",{"id":2163,"sortIndex":221,"researcher":20,"roles":2164,"affiliations":2165,"properties":2181},"149fb1cb-053b-41f8-bc97-d74e4ed32c18",[980],[2166,2172],{"id":2126,"sortIndex":21,"affiliation":2167,"properties":20},{"id":2126,"createTime":20,"updateTime":20,"relativeEntities":2168,"slug":20,"properties":2169,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2171,"statistic":20},[],{"title":2170},{"VI":2131},[],{"id":2173,"sortIndex":99,"affiliation":2174,"properties":2180},"24234d99-7ab9-4f24-8a3d-29f86b88fe36",{"id":2173,"createTime":20,"updateTime":20,"relativeEntities":2175,"slug":20,"properties":2176,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2179,"statistic":20},[],{"title":2177},{"EN":2178},"Università degli studi di Milano, Milano, Italy",[],{},{"title":2182},{"VI":2183},"Giuseppe Pelosi",{"id":2185,"sortIndex":241,"researcher":20,"roles":2186,"affiliations":2187,"properties":2196},"9b0eadd3-232f-4f30-b29f-51930d7b0823",[980],[2188],{"id":2189,"sortIndex":21,"affiliation":2190,"properties":20},"7d37f9b5-38d1-42c9-b4d1-b71f6f4aba55",{"id":2189,"createTime":20,"updateTime":20,"relativeEntities":2191,"slug":20,"properties":2192,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2195,"statistic":20},[],{"title":2193},{"VI":2194},"Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",[],{"title":2197},{"VI":2198},"Nicola Nicolai",{"id":2200,"sortIndex":417,"researcher":20,"roles":2201,"affiliations":2202,"properties":2209},"b952706f-ac2c-4a2d-84cb-c6b8dbb4f531",[980],[2203],{"id":1997,"sortIndex":21,"affiliation":2204,"properties":20},{"id":1997,"createTime":20,"updateTime":20,"relativeEntities":2205,"slug":20,"properties":2206,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2208,"statistic":20},[],{"title":2207},{"VI":2002},[],{"title":2210},{"VI":2211},"Giuseppe Procopio",{"id":2213,"sortIndex":148,"researcher":20,"roles":2214,"affiliations":2215,"properties":2222},"76378399-84f4-434e-adf5-68506a3fe5c8",[980],[2216],{"id":2189,"sortIndex":21,"affiliation":2217,"properties":20},{"id":2189,"createTime":20,"updateTime":20,"relativeEntities":2218,"slug":20,"properties":2219,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2221,"statistic":20},[],{"title":2220},{"VI":2194},[],{"title":2223},{"VI":2224},"Roberto Salvioni",{"id":2226,"sortIndex":293,"researcher":20,"roles":2227,"affiliations":2228,"properties":2242},"87d6a847-5307-405d-b1a2-862bb72aabb9",[980],[2229,2235],{"id":1997,"sortIndex":21,"affiliation":2230,"properties":20},{"id":1997,"createTime":20,"updateTime":20,"relativeEntities":2231,"slug":20,"properties":2232,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2234,"statistic":20},[],{"title":2233},{"VI":2002},[],{"id":2173,"sortIndex":99,"affiliation":2236,"properties":2241},{"id":2173,"createTime":20,"updateTime":20,"relativeEntities":2237,"slug":20,"properties":2238,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2240,"statistic":20},[],{"title":2239},{"EN":2178},[],{},{"title":2243},{"VI":2244},"Filippo G. De Braud",{"url":1990,"publisher":2246,"properties":2296},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2247,"slug":10,"properties":2248,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2252,"manageAffiliations":2265,"indexDatabases":2276,"url":94,"thumbnailPath":20,"statistic":2291,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":2249,"title":2250,"eissn":2251},{"VOID":13},{"EN":15},{"VOID":17},[2253,2257,2261],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2254,"label":2255,"description":2256,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2258,"label":2259,"description":2260,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2262,"label":2263,"description":2264,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[2266,2271],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":2267,"slug":20,"properties":2268,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2270,"statistic":20},[],{"title":2269},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":2272,"slug":20,"properties":2273,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2275,"statistic":20},[],{"title":2274},{"EN":54},[],[2277,2284],{"id":58,"indexDatabase":2278,"url":71,"indexYears":20,"academicFieldIds":2283,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":2279,"label":2280,"description":2281,"key":67,"publicationTags":2282,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":2285,"url":87,"indexYears":88,"academicFieldIds":2290,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":2286,"label":2287,"description":2288,"key":84,"publicationTags":2289,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":2292,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":2293,"totalCitation":21,"totalCitationByYear":2294,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2295,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":2297,"volume":2299},{"VOID":2298},"236-242",{"VOID":2300},"34","2016-02-12",[69,93],{"id":2304,"createTime":2305,"updateTime":2306,"relativeEntities":2307,"slug":2308,"properties":2309,"entityType":972,"verifyStatus":127,"verifyTime":2306,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":2318,"fullTextUrl":20,"authors":2319,"publicationType":1060,"publisherRelationship":2425,"citationCount":20,"citationInfo":20,"publishDate":2481,"publishYear":2482,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":2483,"openAccess":20,"references":20,"isForceReanalyzing":1120},"01e2c54d-4ab1-4042-8b34-9ab4134ad921","2024-01-16T23:26:10.049+00:00","2024-12-18T19:22:23.964+00:00",[],"Biochemical-Modulation-of-5-Fluorouacil-Through-Dihydropyrimidine-Dehydrogenase-Inhibition-a-Southwest-Oncology-Group-Phase-II-Trial-of-Eniluracil-and-5-Fluorouracil-in-Advanced-Resistant-Colorectal-Cancer",{"abstract":2310,"title":2312,"references":2314,"doi":2316},{"EN":2311},"\nPurpose. To investigate thehypothesis that a systemic agent designedto inhibit dihydropyrimidine dehydrogenase(DPD), the first enzyme in thefluoropyrimidine degradative pathway, couldimprove the effective amount of5-fluorouracil (5-FU) delivered to a tumorresulting in enhanced response. \nPatients and methods. Eligibility includedcytologically or pathologically verifieddiagnosis of colorectal cancer thatrecurred during or within 12 months ofcompletion of adjuvant therapy,representing patients generally consideredresistant to fluorinated pyrimidinetherapy. Stratification was into twocohorts: recurrence while receivingadjuvant therapy, and relapse within 12months of completing adjuvant therapy.Treatment consisted of 28 days of oraltherapy every five weeks with eniluraciland 5-FU administered in a 10:1 ratio. Thedaily dose of eniluracil was 10 mg\u002Fm2with 5-FU 1 mg\u002Fm2, divided into twodoses. \nResults. Twenty-five patientsare evaluable for response: 9 relapsedduring therapy and 16 relapsed within oneyear of adjuvant therapy. In the firstgroup, there was one partial response (9%;95% CI 0–41%); in the second cohort therewas one confirmed complete response (5%;95% CI 0–23%) and one unconfirmed partialresponse, for an overall response rate of10%. \nConclusions. This regimen lackssignificant activity in this targetpopulation. Pre-treatment intratumoral DPDexpression was not assessed, therefore themechanism of fluorinated pyrimidineresistance cannot be specificallyattributed to elevated DPD levels.Attempting restoration of chemotherapysensitivity through blockade of enzymes orsignal transduction molecules responsiblefor resistance is rational, provided thattumor target expression is the basis fortrial entry.",{"EN":2313},"Biochemical Modulation of 5-Fluorouacil Through Dihydropyrimidine Dehydrogenase Inhibition: a Southwest Oncology Group Phase II Trial of Eniluracil and 5-Fluorouracil in Advanced Resistant Colorectal Cancer",{"VOID":2315},"Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Maillard JA, Laurie JA, Tschetter LK, Wiesenfield M: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407–1418, 1989\nAdvanced Colorectal Cancer Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896–903, 1992\nLeichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS: Phase II study of 5-FU and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13(6):1303–1311, 1995\nCorfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921–928, 1995\nO'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller D, Arbuck SG, Weiner LM, Mayer RJ, Bebson AB III: Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - an Easter Cooperative Oncology Group\u002FCancer and Leukemia Group B study. J Clin Oncol 19:2413–2421, 2001.\nO'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Weiand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295–300, 1998\nMoertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillard JA: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358, 1990\nHeggie GD, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 47:2203–2206, 1987\nShousong C, Yousef MR, Spector T: 5-ethynyluracil (776C85): modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507–1510, 1994\nBaker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Onocl 14:3085–3096, 1996\nSchilsky RL, Hohneker JA, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA III: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450–1457, 1998\nBurroughs Wellcome: 776C85: Updated (3\u002F95) summary of non-clinical and clinical (Phase I) data\nSlamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter, J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792, 2001\nBergsland E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Gaudreault J, Lieberman G, Kabbinavar F: A Randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil\u002Fleucovorin (FU\u002FLV) to FU\u002FLV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 19:939, 2000",{"VOID":2317},"10.1023\u002FA:1020662113061","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1023\u002FA:1020662113061",[2320,2335,2348,2363,2378,2395,2410],{"id":2321,"sortIndex":21,"researcher":20,"roles":2322,"affiliations":2323,"properties":2332},"016fc97b-0083-4e09-938a-8ae6c6721405",[980],[2324],{"id":2325,"sortIndex":21,"affiliation":2326,"properties":20},"8c2e0daa-2743-4459-9f23-8c69c17b6ace",{"id":2325,"createTime":20,"updateTime":20,"relativeEntities":2327,"slug":20,"properties":2328,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2331,"statistic":20},[],{"title":2329},{"VI":2330},"Comprehensive Cancer Centers of the Desert, Palm Springs, USA",[],{"title":2333},{"VI":2334},"Cynthia G. Leichman",{"id":2336,"sortIndex":99,"researcher":20,"roles":2337,"affiliations":2338,"properties":2345},"ad2c777a-6f6f-4d18-bed3-3939a6ac1aac",[980],[2339],{"id":1538,"sortIndex":21,"affiliation":2340,"properties":20},{"id":1538,"createTime":20,"updateTime":20,"relativeEntities":2341,"slug":20,"properties":2342,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2344,"statistic":20},[],{"title":2343},{"VI":1543},[],{"title":2346},{"VI":2347},"Kari Chansky",{"id":2349,"sortIndex":100,"researcher":20,"roles":2350,"affiliations":2351,"properties":2360},"11fbae2f-61af-425c-9deb-fc1007f079a9",[980],[2352],{"id":2353,"sortIndex":21,"affiliation":2354,"properties":20},"4165ce99-f875-40be-9ce9-e517cae9a893",{"id":2353,"createTime":20,"updateTime":20,"relativeEntities":2355,"slug":20,"properties":2356,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2359,"statistic":20},[],{"title":2357},{"VI":2358},"St. Vincent's CCC, New York, USA",[],{"title":2361},{"VI":2362},"John S. Macdonald",{"id":2364,"sortIndex":101,"researcher":20,"roles":2365,"affiliations":2366,"properties":2375},"758b6758-d7a5-42a9-9a39-7e1175884d2a",[980],[2367],{"id":2368,"sortIndex":21,"affiliation":2369,"properties":20},"e75c9c78-5728-4789-8a92-67f545b11752",{"id":2368,"createTime":20,"updateTime":20,"relativeEntities":2370,"slug":20,"properties":2371,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2374,"statistic":20},[],{"title":2372},{"VI":2373},"University of Kentucky Medical Center, Lexington, USA",[],{"title":2376},{"VI":2377},"Michael A. Doukas",{"id":2379,"sortIndex":142,"researcher":20,"roles":2380,"affiliations":2381,"properties":2393},"832be778-0234-4bbe-bb64-4da9e5365b6c",[980],[2382],{"id":2383,"sortIndex":21,"affiliation":2384,"properties":2390},"49ac0a44-60a6-430a-916c-eca4080f055f",{"id":2383,"createTime":20,"updateTime":20,"relativeEntities":2385,"slug":20,"properties":2386,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2389,"statistic":20},[],{"title":2387},{"VI":2388},"Cleveland Clinic Foundation, Cleveland, United States",[],{"title":2391},{"VI":2392},"Cleveland Clinic Foundation, Cleveland, USA",{"title":2394},{"VI":1033},{"id":2396,"sortIndex":143,"researcher":20,"roles":2397,"affiliations":2398,"properties":2407},"a924434f-c1a4-482c-ad8e-f7583caf4ff2",[980],[2399],{"id":2400,"sortIndex":21,"affiliation":2401,"properties":20},"71b51a3e-2e7c-4255-a23f-e82321f2e48d",{"id":2400,"createTime":20,"updateTime":20,"relativeEntities":2402,"slug":20,"properties":2403,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2406,"statistic":20},[],{"title":2404},{"VI":2405},"Greenville CCOP, Greenville, USA",[],{"title":2408},{"VI":2409},"Jeffrey K. Giguere",{"id":2411,"sortIndex":145,"researcher":20,"roles":2412,"affiliations":2413,"properties":2422},"0d795273-6da8-4f28-bae7-27ff98ab3824",[980],[2414],{"id":2415,"sortIndex":21,"affiliation":2416,"properties":20},"6fe8bf52-8b3b-47cb-a5ca-dce8fed1d3a8",{"id":2415,"createTime":20,"updateTime":20,"relativeEntities":2417,"slug":20,"properties":2418,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2421,"statistic":20},[],{"title":2419},{"VI":2420},"MD Anderson Cancer Center, University of Texas, Houston, USA",[],{"title":2423},{"VI":2424},"James L. Abbruzzese",{"url":2318,"publisher":2426,"properties":2476},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2427,"slug":10,"properties":2428,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2432,"manageAffiliations":2445,"indexDatabases":2456,"url":94,"thumbnailPath":20,"statistic":2471,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":2429,"title":2430,"eissn":2431},{"VOID":13},{"EN":15},{"VOID":17},[2433,2437,2441],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2434,"label":2435,"description":2436,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2438,"label":2439,"description":2440,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2442,"label":2443,"description":2444,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[2446,2451],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":2447,"slug":20,"properties":2448,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2450,"statistic":20},[],{"title":2449},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":2452,"slug":20,"properties":2453,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2455,"statistic":20},[],{"title":2454},{"EN":54},[],[2457,2464],{"id":58,"indexDatabase":2458,"url":71,"indexYears":20,"academicFieldIds":2463,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":2459,"label":2460,"description":2461,"key":67,"publicationTags":2462,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":2465,"url":87,"indexYears":88,"academicFieldIds":2470,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":2466,"label":2467,"description":2468,"key":84,"publicationTags":2469,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":2472,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":2473,"totalCitation":21,"totalCitationByYear":2474,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2475,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":2477,"volume":2479},{"VOID":2478},"419-424",{"VOID":2480},"20","2002-11-01",2002,[69,93],{"id":2485,"createTime":2486,"updateTime":2487,"relativeEntities":2488,"slug":2489,"properties":2490,"entityType":972,"verifyStatus":127,"verifyTime":2487,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":2499,"fullTextUrl":20,"authors":2500,"publicationType":1060,"publisherRelationship":2557,"citationCount":20,"citationInfo":20,"publishDate":2613,"publishYear":2614,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":2615,"openAccess":20,"references":20,"isForceReanalyzing":1120},"01ece309-d4e4-45d9-8d5f-6df0f465b90c","2023-12-06T16:45:46.723+00:00","2024-12-22T09:40:03.791+00:00",[],"The-clinical-efficiency-of-TACE-combined-with-simultaneous-computed-tomography-guided-radiofrequency-ablation-for-advanced-hepatocellular-carcinoma",{"abstract":2491,"title":2493,"references":2495,"doi":2497},{"EN":2492},"Background To investigate the clinical efficiency of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) for advanced hepatocellular carcinoma (HCC). Methods This retrospective study enrolled 177 HCC patients, and they were divided into TACE monotherapy group (n = 129) and TACE + RFA group (n = 48) between January 2015 and October 2017. The objective response rate (ORR), disease control rate (DCR), and the survival outcomes were compared between the TACE monotherapy and the treatment of TACE + RFA after propensity score matching (PSM). Results After PSM matching, the confounding factors had no significant differences between the 48 pairs of patients. The DCR was calculated as 33 (69 %) and 42 (88 %) for the TACE monotherapy group and TACE + RFA group, respectively (P \u003C 0.05). And the ORR was calculated as 23 (48 %) and 35 (73 %), respectively (P \u003C 0.05). Moreover, the PFS rate of the TACE + RFA group was significantly higher than the TACE alone group (P \u003C 0.001). Conclusions The treatment of TACE combined with RFA has better tumor response rate and survival rate than the TACE monotherapy for patients with advanced HCC.",{"EN":2494},"The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma",{"VOID":2496},"Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A, World Gastroenterology Organization (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44:239–245. https:\u002F\u002Fdoi.org\u002F10.1097\u002FMCG.0b013e3181d46ef2\nMazzanti R, Gramantieri L, Bolondi L (2008) Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29:130–143. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.mam.2007.09.008\nChen JG, Zhang SW (2011) Liver cancer epidemic in China: past, present and future. Semin Cancer Biol 21:59–69. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.semcancer.2010.11.002\nBruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fhep.24199\nQin LX, Tang ZY (2002) The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 8:193–199. https:\u002F\u002Fdoi.org\u002F10.3748\u002Fwjg.v24.i35.4000\nde Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC (2016) Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 39:334–343. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00270-015-1208-y\nCommittee AT, Navaneethan U, Thosani N, Goodman A, Manfredi M, Pannala R, Parsi MA, Smith ZL, Sullivan SA, Banerjee S, Maple JT (2017) Radiofrequency ablation devices. VideoGIE 2:252–259. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.vgie.2017.06.002\nPeng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700. https:\u002F\u002Fdoi.org\u002F10.1148\u002Fradiol.11110637\nTakuma Y, Takabatake H, Morimoto Y, Toshikuni N, Kayahara T, Makino Y, Yamamoto H (2013) Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology 269:927–937. https:\u002F\u002Fdoi.org\u002F10.1148\u002Fradiol.13130387\nKrajewski KM, Nishino M, Ramaiya NH, Choueiri TK (2015) RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol 204:W282-W288. https:\u002F\u002Fdoi.org\u002F10.2214\u002FAJR.14.13236\nLiu X, Liao G, Luo X, Song W, Zhang H, Chen H, Cai S, Guo D (2020) Hepatocellular carcinoma with different areas of right retroperitoneal space invasion: evaluation of transcatheter arterial chemoembolization efficacy and blood supply characteristics. Front Oncol 10:539692. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffonc.2020.539692\nLivraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, Gazelle GS (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214:761–768. https:\u002F\u002Fdoi.org\u002F10.1148\u002Fradiology.214.3.r00mr02761\nChuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L (2011) Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther 12(10):865–871. https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcbt.12.10.17676\nGarwood ER, Fidelman N, Hoch SE, Kerlan RK Jr, Yao FY (2013) Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 19(2):164–173. https:\u002F\u002Fdoi.org\u002F10.1002\u002Flt.23552\nMirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, Ames FC, Singletary SE (2001) Radiofrequency ablation of solid tumors. Cancer J 7:95–102\nAl-Sakere B, Bernat C, Andre F, Connault E, Opolon P, Davalos RV, Mir LM (2007) A study of the immunological response to tumor ablation with irreversible electroporation. Technol Cancer Res Treat 6(4):301–336. https:\u002F\u002Fdoi.org\u002F10.1177\u002F153303460700600406\nMauri G, Nicosia L, Xu Z, Di Pietro S, Monfardini L, Bonomo G, Varano GM, Prada F, Della Vigna P, Orsi F (2018) Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer. Br J Radiol 91(1083):20170641. https:\u002F\u002Fdoi.org\u002F10.1259\u002Fbjr.20170641\nKagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T, Tokai, RFA Study Group (2010) Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 116:3638–3644. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcncr.25142\nNi JY, Liu SS, Xu LF, Sun HL, Chen YT (2013) Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 19:3872–3882. https:\u002F\u002Fdoi.org\u002F10.3748\u002Fwjg.v19.i24.3872\nYi Y, Zhang Y, Wei Q, Zhao L, Han J, Song Y, Ding Y, Lu G, Liu J, Ding H, Dai F, Tang X (2014) Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res 26(1):112–118. https:\u002F\u002Fdoi.org\u002F10.3978\u002Fj.issn.1000-9604.2014.02.09\nPeng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31(4):426–432. https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2012.42.9936\nAbdelaziz AO, Abdelmaksoud AH, Nabeel MM, Shousha HI, Cordie AA, Mahmoud ShH, Medhat E, Omran D, Elbaz TM (2017) Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev 18(1):189–194. https:\u002F\u002Fdoi.org\u002F10.22034\u002FAPJCP.2017.18.1.189",{"VOID":2498},"10.1007\u002Fs10637-021-01101-w","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10637-021-01101-w",[2501,2516,2529,2544],{"id":2502,"sortIndex":21,"researcher":20,"roles":2503,"affiliations":2504,"properties":2513},"f2f3c9f5-919a-4c00-87d2-ca1707c3e4a9",[980],[2505],{"id":2506,"sortIndex":21,"affiliation":2507,"properties":20},"0d729c78-aeca-4c8d-844e-d1d0e56a8ffb",{"id":2506,"createTime":20,"updateTime":20,"relativeEntities":2508,"slug":20,"properties":2509,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2512,"statistic":20},[],{"title":2510},{"VI":2511},"Department of Hematology and Oncology (Key Discipline of Jiangsu Medicine), Medical School, Zhongda Hospital, Southeast University, Nanjing, People’s Republic of China",[],{"title":2514},{"VI":2515},"Peng Yuan",{"id":2517,"sortIndex":99,"researcher":20,"roles":2518,"affiliations":2519,"properties":2526},"8248ad83-8aba-4c6d-9eb0-264395567ea5",[980],[2520],{"id":2506,"sortIndex":21,"affiliation":2521,"properties":20},{"id":2506,"createTime":20,"updateTime":20,"relativeEntities":2522,"slug":20,"properties":2523,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2525,"statistic":20},[],{"title":2524},{"VI":2511},[],{"title":2527},{"VI":2528},"Fei Wang",{"id":2530,"sortIndex":100,"researcher":20,"roles":2531,"affiliations":2532,"properties":2541},"c59a62c0-6a9d-4ab0-bca0-650f2def7d55",[980],[2533],{"id":2534,"sortIndex":21,"affiliation":2535,"properties":20},"34a72007-04be-440c-a207-50080fd5f913",{"id":2534,"createTime":20,"updateTime":20,"relativeEntities":2536,"slug":20,"properties":2537,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2540,"statistic":20},[],{"title":2538},{"VI":2539},"Department of Interventional Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China",[],{"title":2542},{"VI":2543},"Guangyu Zhu",{"id":2545,"sortIndex":101,"researcher":20,"roles":2546,"affiliations":2547,"properties":2554},"8d386ab5-c567-441f-94f4-f3f0bc285404",[980],[2548],{"id":2506,"sortIndex":21,"affiliation":2549,"properties":20},{"id":2506,"createTime":20,"updateTime":20,"relativeEntities":2550,"slug":20,"properties":2551,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2553,"statistic":20},[],{"title":2552},{"VI":2511},[],{"title":2555},{"VI":2556},"Baoan Chen",{"url":2499,"publisher":2558,"properties":2608},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2559,"slug":10,"properties":2560,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2564,"manageAffiliations":2577,"indexDatabases":2588,"url":94,"thumbnailPath":20,"statistic":2603,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":2561,"title":2562,"eissn":2563},{"VOID":13},{"EN":15},{"VOID":17},[2565,2569,2573],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2566,"label":2567,"description":2568,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2570,"label":2571,"description":2572,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2574,"label":2575,"description":2576,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[2578,2583],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":2579,"slug":20,"properties":2580,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2582,"statistic":20},[],{"title":2581},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":2584,"slug":20,"properties":2585,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2587,"statistic":20},[],{"title":2586},{"EN":54},[],[2589,2596],{"id":58,"indexDatabase":2590,"url":71,"indexYears":20,"academicFieldIds":2595,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":2591,"label":2592,"description":2593,"key":67,"publicationTags":2594,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":2597,"url":87,"indexYears":88,"academicFieldIds":2602,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":2598,"label":2599,"description":2600,"key":84,"publicationTags":2601,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":2604,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":2605,"totalCitation":21,"totalCitationByYear":2606,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2607,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":2609,"volume":2611},{"VOID":2610},"1383-1388",{"VOID":2612},"39","2021-03-22",2021,[69,93],{"id":2617,"createTime":2618,"updateTime":2619,"relativeEntities":2620,"slug":2621,"properties":2622,"entityType":972,"verifyStatus":127,"verifyTime":2619,"verifyNote":974,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":2631,"fullTextUrl":20,"authors":2632,"publicationType":1060,"publisherRelationship":2721,"citationCount":20,"citationInfo":20,"publishDate":2777,"publishYear":2778,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":2779,"openAccess":20,"references":20,"isForceReanalyzing":1120},"01f4f43a-2191-48d3-84e4-114ee8095cc0","2024-01-23T02:42:04.182+00:00","2024-12-08T09:47:19.484+00:00",[],"Phase-II-trial-of-menogaril-in-advanced-colorectal-cancer",{"abstract":2623,"title":2625,"references":2627,"doi":2629},{"EN":2624},"Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg\u002Fsqm or 200 mg\u002Fsqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63% of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13% of the patients. Nausea\u002Fvomiting (66%) and alopecia (50%) were of mild-moderate degree. This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer.",{"EN":2626},"Phase II trial of menogaril in advanced colorectal cancer",{"VOID":2628},"Bhuyan BK, Neil GL, Li LH, McGovren JP, Wiley PF: Chemistry and biological activity of 7-con-O-methylnogaril (7-con-OMEN). In: ST Crooke, SD Reich (eds) Anthracyclines: Current Status and New Developments. Academic Press, New York 1980, pp 365–395\nMcGovren JP, Nelson KG, Lassus M, Cradock JC, Plowman J, Christopher JP: Menogaril: a new anthracycline agent entering clinical trials. Invest New Drugs 2:359–367, 1984\nDodion P, Sanders C, Rombaut W, Rozencweig M, Kitt MM, Kenis Y, Klastersky J: Activity of menogaril and N-demethylmenogaril in a human tumor cloning assay. Eur J Cancer Clin Oncol 22:245–249, 1986\nDodion P, Sessa C, Joss R, Crespeigne N, Willems Y, Kitt M, Abrams J, Finet C, Brewer JE, Adams WJ, Earhart RH, Rozencweig M, Kenis Y, Cavalli F: Phase I study of intravenous menogaril administered intermittently. J Clin Oncol 4:767–774, 1986\nDorr FA, Von Hoff DD, Kuhn JG, Schwartz R, Kisner DL: Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Cancer Res 46:2562–2565, 1986\nSigman LM, Van Echo DA, Egorin MJ, Whitacre MY, Aisner J: Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. Cancer Treat Rep 70:721–725, 1986",{"VOID":2630},"10.1007\u002FBF00175404","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002FBF00175404",[2633,2648,2663,2676,2691,2706],{"id":2634,"sortIndex":21,"researcher":20,"roles":2635,"affiliations":2636,"properties":2645},"df63e67d-a5cb-4c11-84c0-8db7802d13ef",[980],[2637],{"id":2638,"sortIndex":21,"affiliation":2639,"properties":20},"b97d1463-075d-4986-985d-19ed53a8d740",{"id":2638,"createTime":20,"updateTime":20,"relativeEntities":2640,"slug":20,"properties":2641,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2644,"statistic":20},[],{"title":2642},{"VI":2643},"Division of Oncology and Hematology, Medizinische Klinik C, Kantonsspital, St Gallen, Switzerland",[],{"title":2646},{"VI":2647},"Eduard E. Holdener",{"id":2649,"sortIndex":99,"researcher":20,"roles":2650,"affiliations":2651,"properties":2660},"4e04940b-9d80-40a8-ac89-b4567768d04e",[980],[2652],{"id":2653,"sortIndex":21,"affiliation":2654,"properties":20},"da00205a-39b7-4271-9401-8bec2f657701",{"id":2653,"createTime":20,"updateTime":20,"relativeEntities":2655,"slug":20,"properties":2656,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2659,"statistic":20},[],{"title":2657},{"VI":2658},"Antoni van Leeuwenhoek Ziekenhuis, CX Amsterdam, The Netherlands",[],{"title":2661},{"VI":2662},"Wim W. ten Bokkel Huinink",{"id":2664,"sortIndex":100,"researcher":20,"roles":2665,"affiliations":2666,"properties":2673},"eeaae34f-65a8-44be-9096-da4971abd04c",[980],[2667],{"id":2638,"sortIndex":21,"affiliation":2668,"properties":20},{"id":2638,"createTime":20,"updateTime":20,"relativeEntities":2669,"slug":20,"properties":2670,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2672,"statistic":20},[],{"title":2671},{"VI":2643},[],{"title":2674},{"VI":2675},"Genevieve Decoster",{"id":2677,"sortIndex":101,"researcher":20,"roles":2678,"affiliations":2679,"properties":2688},"47f2b7b2-77d5-4e91-a90a-d0a5d5034a80",[980],[2680],{"id":2681,"sortIndex":21,"affiliation":2682,"properties":20},"7699abb7-b1a5-4902-9083-2069adf3871c",{"id":2681,"createTime":20,"updateTime":20,"relativeEntities":2683,"slug":20,"properties":2684,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2687,"statistic":20},[],{"title":2685},{"VI":2686},"Department of Oncology, Kantonsspital, Basle, Switzerland",[],{"title":2689},{"VI":2690},"Christian Ludwig",{"id":2692,"sortIndex":142,"researcher":20,"roles":2693,"affiliations":2694,"properties":2703},"fa3f9827-c8d5-4b82-ad26-425a9b4bb9cf",[980],[2695],{"id":2696,"sortIndex":21,"affiliation":2697,"properties":20},"23932813-0a55-4cd2-82ae-2232b78c5ce0",{"id":2696,"createTime":20,"updateTime":20,"relativeEntities":2698,"slug":20,"properties":2699,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2702,"statistic":20},[],{"title":2700},{"VI":2701},"EORTC Data Center, Brussels, Belgium",[],{"title":2704},{"VI":2705},"Georgette Renard",{"id":2707,"sortIndex":143,"researcher":20,"roles":2708,"affiliations":2709,"properties":2718},"5091c65c-a110-4eeb-9b67-f0e9ad132744",[980],[2710],{"id":2711,"sortIndex":21,"affiliation":2712,"properties":20},"6e1ad8a2-8779-46bd-94d5-558e5a206fe7",{"id":2711,"createTime":20,"updateTime":20,"relativeEntities":2713,"slug":20,"properties":2714,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2717,"statistic":20},[],{"title":2715},{"VI":2716},"Department of Oncology, Free University Hospital, HV Amsterdam, The Netherlands",[],{"title":2719},{"VI":2720},"Herbert M. Pinedo",{"url":2631,"publisher":2722,"properties":2772},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2723,"slug":10,"properties":2724,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2728,"manageAffiliations":2741,"indexDatabases":2752,"url":94,"thumbnailPath":20,"statistic":2767,"gsStatistic":20,"type":104,"analyzePriority":20},[],{"issn":2725,"title":2726,"eissn":2727},{"VOID":13},{"EN":15},{"VOID":17},[2729,2733,2737],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2730,"label":2731,"description":2732,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2734,"label":2735,"description":2736,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2738,"label":2739,"description":2740,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},[2742,2747],{"id":43,"createTime":20,"updateTime":20,"relativeEntities":2743,"slug":20,"properties":2744,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2746,"statistic":20},[],{"title":2745},{"EN":47},[],{"id":50,"createTime":20,"updateTime":20,"relativeEntities":2748,"slug":20,"properties":2749,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2751,"statistic":20},[],{"title":2750},{"EN":54},[],[2753,2760],{"id":58,"indexDatabase":2754,"url":71,"indexYears":20,"academicFieldIds":2759,"indexDatabaseRanking":20},{"id":60,"createTime":20,"updateTime":20,"relativeEntities":2755,"label":2756,"description":2757,"key":67,"publicationTags":2758,"standard":20},[],{"EN":63,"VI":63},{"EN":65,"VI":66},[69,70],[73,74],{"id":76,"indexDatabase":2761,"url":87,"indexYears":88,"academicFieldIds":2766,"indexDatabaseRanking":93},{"id":78,"createTime":20,"updateTime":20,"relativeEntities":2762,"label":2763,"description":2764,"key":84,"publicationTags":2765,"standard":20},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90,91,92],{"impactFactor":21,"impactFactorByYear":2768,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":97,"totalPublicationByYear":2769,"totalCitation":21,"totalCitationByYear":2770,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2771,"hindexLast5Year":21,"hindex":21},{},{"1986":99,"1991":99,"1992":99,"1996":99,"1997":99,"1998":99,"2003":99,"2005":100,"2006":99,"2007":100,"2008":101,"2009":101,"2010":99,"2011":99,"2012":99,"2013":100,"2017":99,"2018":99,"2019":99,"2020":99,"2021":99,"2022":99,"2023":100},{},{},{"pages":2773,"volume":2775},{"VOID":2774},"227-230",{"VOID":2776},"6","1988-09-01",1988,[69,93]]